

**AFRL-RH-FS-TR-2012-0008**

**Mechanisms of Organophosphorus (OP) Injury: Sarin-Induced  
Hippocampal Gene Expression Changes and Pathway Perturbation**



**Victor T. Chan  
Armando Soto  
Jessica A. Wagner  
Brandy S. Watts**

**Bioeffects Division  
Molecular Bioeffects Branch**

**Amy D. Walters  
Tiffany M. Hill**

**Henry M. Jackson Foundation for the  
Advancement of Military Medicine**

**January 2012**

**Final Report for October 2009 to October 2011**

**Distribution A: Approved for public  
release; distribution unlimited.**

**Air Force Research Laboratory  
711<sup>th</sup> Human Performance Wing  
Human Effectiveness Directorate  
Bioeffects Division  
Molecular Bioeffects Branch  
Wright-Patterson AFB OH 45433-5707**


## NOTICE

Using Government drawings, specifications, or other data included in this document for any purpose other than Government procurement does not in any way obligate the U.S. Government. The fact that the Government formulated or supplied the drawings, specifications, or other data does not license the holder or any other person or corporation; or convey any rights or permission to manufacture, use, or sell any patented invention that may relate to them.

This report was cleared for public release by the 88<sup>th</sup> Air Base Wing Public Affairs Office and is available to the general public, including foreign nationals. Copies may be obtained from the Defense Technical Information Center (DTIC) (<http://www.dtic.mil>).

**AFRL-RH-FS-TR-2012-0008**

THIS REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION IN  
ACCORDANCE WITH ASSIGNED DISTRIBUTION STATEMENT.



Armando Soto  
Work Unit Manager  
Molecular Bioeffects Branch  
Bioeffects Division  
Human Effectiveness Directorate  
711th Human Performance Wing  
Air Force Research Laboratory



Garrett D. Polhamus, DR-IV, DAF  
Chief, Bioeffects Division  
Human Effectiveness Directorate  
711th Human Performance Wing  
Air Force Research Laboratory

This report is published in the interest of scientific and technical information exchange, and its publication does not constitute the Government's approval or disapproval of its ideas or findings.

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |             |                         |                               | Form Approved<br>OMB No. 0704-0188                                   |                                                 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------------------|-------------------------------|----------------------------------------------------------------------|-------------------------------------------------|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |             |                         |                               |                                                                      |                                                 |
| 1. REPORT DATE (DD-MM-YYYY)<br>15 Jan 2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |             | 2. REPORT TYPE<br>Final |                               | 3. DATES COVERED (From - To)<br>October 2009 – September 2011        |                                                 |
| 4. TITLE AND SUBTITLE<br>Mechanisms of Organophosphorus (OP) Injury: Sarin-Induced Hippocampal Gene Expression Changes and Pathway Perturbation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                         |                               | 5a. CONTRACT NUMBER<br>NA                                            |                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                         |                               | 5b. GRANT NUMBER<br>NA                                               |                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                         |                               | 5c. PROGRAM ELEMENT NUMBER                                           |                                                 |
| 6. AUTHOR(S)<br>*Victor T Chan; *Armando Soto; *Jessica A. Wagner; **Amy D. Walters; *Tiffany M. Hill;<br>*Brandy S. Watts                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |             |                         |                               | 5d. PROJECT NUMBER<br>ODT                                            |                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                         |                               | 5e. TASK NUMBER<br>WP                                                |                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                         |                               | 5f. WORK UNIT NUMBER<br>ODTWP001                                     |                                                 |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>**Henry M. Jackson Foundation for the Advancement of Military Medicine, Wright<br>Wright-Patterson AFB OH 45433                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |             |                         |                               | 8. PERFORMING ORGANIZATION REPORT<br>NUMBER                          |                                                 |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>Air Force Materiel Command*<br>Air Force Research Laboratory<br>711 Human Performance Wing<br>Human Effectiveness Directorate<br>Bioeffects Division<br>Molecular Bioeffects Branch<br>Wright-Patterson AFB OH 45433-5707                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |             |                         |                               | 10. SPONSOR/MONITOR'S ACRONYM(S)<br>711 HPW/RHDJ                     |                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                         |                               | 11. SPONSOR/MONITOR'S REPORT<br>NUMBER(S)<br>AFRL-RH-FS-TR-2012-0008 |                                                 |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT<br>Distribution A: Approved for public release; distribution unlimited.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |             |                         |                               |                                                                      |                                                 |
| 13. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |             |                         |                               |                                                                      |                                                 |
| 14. ABSTRACT<br>This project aimed to investigate the molecular mechanism(s) of organ injury following exposure to sublethal doses of the organophosphorus agent, sarin. The lethal toxic effect of sarin exposure is caused by irreversible inhibition of acetylcholinesterase (AChE) and subsequently excessive stimulation of postsynaptic cholinergic receptors. However, much less is known about the effects of low-dose sarin exposure on functions of critical brain regions. Neurotoxicity caused by sarin exposure can be mediated by pathways independent of the cholinergic system. Since the hippocampus plays an important role in cognitive functions (including learning and memory), and is one of the most sensitive brain regions to sarin-induced injury, the focus of this study is to investigate differential gene expression and pathway perturbation in this brain region, using microarray technology combined with advanced bioinformatics. Sarin treatment resulted in differential expression of a large number of genes. Most of these genes showed increased expression, especially at the 6-hour and 25-day time points. However, significant gene repression was observed at the 10-day time point. Pathway analysis revealed that one of the direct effects of sarin cellular toxicity could be related to DNA damage and inhibition of the glutathione antioxidant system, which triggered the up-regulation of the apoptotic pathways at early time points. |             |                         |                               |                                                                      |                                                 |
| 15. SUBJECT TERMS<br>Organophosphorus    sarin exposure    acetylcholinesterase    cognitive functions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |             |                         |                               |                                                                      |                                                 |
| 16. SECURITY CLASSIFICATION OF:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                         | 17. LIMITATION<br>OF ABSTRACT | 18. NUMBER<br>OF PAGES                                               | 19a. NAME OF RESPONSIBLE PERSON                 |
| a. REPORT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | b. ABSTRACT | c. THIS PAGE            |                               |                                                                      | Armando Soto                                    |
| U                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | U           | U                       | SAR                           | 74                                                                   | 19b. TELEPHONE NUMBER (include area code)<br>NA |

Standard Form 298 (Rev. 8-98)  
Prescribed by ANSI Std. Z39.18

**THIS PAGE INTENTIONALLY LEFT BLANK.**

## TABLE OF CONTENTS

| Section                                                                                                                       | Page |
|-------------------------------------------------------------------------------------------------------------------------------|------|
| LIST OF TABLES .....                                                                                                          | v    |
| PREFACE .....                                                                                                                 | vii  |
| ACKNOWLEDGEMENTS .....                                                                                                        | viii |
| SUMMARY .....                                                                                                                 | ix   |
| 1. INTRODUCTION .....                                                                                                         | 1-3  |
| 1.1 Toxicity of Sarin Exposure .....                                                                                          | 1    |
| 1.2 Mechanistic Analysis of Sarin-Induced Organ Injury .....                                                                  | 1    |
| 1.3 Molecular Mechanism of Sarin-Induced Hippocampal Injury .....                                                             | 2    |
| 2. METHODS AND MATERIALS .....                                                                                                | 3-8  |
| 2.1 General Procedures .....                                                                                                  | 3    |
| 2.2 Determination of Mean Lethal Dose (LD50) for Sarin .....                                                                  | 3    |
| 2.3 Treatment of Animals with 0.4x, 0.6x and 0.75x LD50 of Sarin .....                                                        | 3    |
| 2.4 Evaluation of Sarin-Induced Toxicity .....                                                                                | 5    |
| 2.4.1 FOB Assessment .....                                                                                                    | 5    |
| 2.4.2 Inhibition of AChE and BuChE .....                                                                                      | 5    |
| 2.5 Collection and Processing Tissue Samples .....                                                                            | 6    |
| 2.6 Transcriptomic Profiling of Hippocampal Region .....                                                                      | 6    |
| 2.7 Identification of Sarin-Induced Hippocampal Gene Expression Changes<br>and Pathway Perturbation .....                     | 7    |
| 3. RESULTS .....                                                                                                              | 9-33 |
| 3.1 Sarin-Induced Toxicity .....                                                                                              | 8    |
| 3.1.1 FOB Assessment .....                                                                                                    | 8    |
| 3.2 Sarin-Induced Toxicity - Inhibition of AChE and BuChE .....                                                               | 11   |
| 3.3 Sarin-Induced Hippocampal Gene Expression Changes .....                                                                   | 13   |
| 3.3.1 Dose Response of Hippocampal Gene Expression Following Sarin Treatment .....                                            | 14   |
| 3.3.2 Temporal Response of Hippocampal Gene Expression Following Sarin Treatment .....                                        | 18   |
| 3.4 Sarin-Induced Hippocampal Pathway Perturbation .....                                                                      | 23   |
| 3.4.1 Gene Expression Process .....                                                                                           | 24   |
| 3.4.1.1 Transcriptional and Posttranscriptional Regulations .....                                                             | 24   |
| 3.4.1.2 Translational and Posttranslational Regulations .....                                                                 | 25   |
| 3.4.1.3 Endomembrane System, Protein Folding and Ubiquitin-Mediated Proteolysis .....                                         | 26   |
| 3.4.2 Signaling Pathways .....                                                                                                | 27   |
| 3.4.3 DNA Damage/Repair, Glutathione Metabolism, Apoptosis and Tissue Repair .....                                            | 28   |
| 3.4.4 Neuronal Growth, Neuron Projection, Synaptic Structure, Synaptic Plasticity and<br>Behavioral/Cognitive Functions ..... | 29   |
| 4. DISCUSSION .....                                                                                                           | 33   |

|                                                                                                              |       |
|--------------------------------------------------------------------------------------------------------------|-------|
| 5. CONCLUSION.....                                                                                           | 37    |
| 6. REFERENCES .....                                                                                          | 38    |
| 7. LIST OF SYMBOLS, ABBREVIATIONS, AND ACRONYMS.....                                                         | 41    |
| 8. Appendix: Supplemental Data .....                                                                         | 42-73 |
| Supplemental Table 1: FOB Scores of Control and Sarin-Treated Animals .....                                  | 42    |
| Supplemental Table 2: Sarin-Induced Inhibition of AChE and BuChE .....                                       | 44    |
| Supplemental Table 3: Sarin-Induced Inhibition of Erythrocyte AChE and Plasma<br>BuChE.....                  | 45    |
| Supplemental Table 4: Sarin-Induced Hippocampal Differential Gene Expression .....                           | 46    |
| Supplemental Figure 1: SOMs of Differential Expressed Genes .....                                            | 47    |
| Supplemental Table 5: Complete Lists of Pathways with Enhancement of<br>Differentially Expressed Genes ..... | 55    |

## LIST OF TABLES

| <b>Table</b>                                                                                                                                                                | <b>Page</b> |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Table 1: Number of Animals in Each Treatment Group.....                                                                                                                     | 4           |
| Table 2: FOB Scoring System Worksheet .....                                                                                                                                 | 6           |
| Table 3: Percentage of Animals with Seizure and Time of First Seizure Occurrence<br>in the 0.75x LD50 Dose Group at Each Time Point .....                                   | 8           |
| Table 4: Dose Response of Sarin-Induced Hippocampal Differential Gene Expression .....                                                                                      | 14          |
| Table 5: Distribution of Differentially Expressed Genes across Dose-Dependent, Dose-<br>Independent and Variable Response Patterns .....                                    | 17          |
| Table 6: Selected Early-Response Genes Following Sarin Treatment .....                                                                                                      | 18          |
| Table 7: Selected Delayed-Response Genes Following Sarin Treatment .....                                                                                                    | 19          |
| Table 8: Selected Late-Response Genes Following Sarin Treatment.....                                                                                                        | 21          |
| Table 9: Selected Persistent Genes Following Sarin Treatment.....                                                                                                           | 21          |
| Table 10: Perturbation of Pathways Involved in Transcriptional and Posttranscriptional<br>Regulations in Hippocampus Following Sarin Treatment.....                         | 24          |
| Table 11: Perturbation of Pathways Involved in Translational and Posttranslational<br>Regulations in Hippocampus Following Sarin Treatment.....                             | 25          |
| Table 12: Perturbation of Pathways Involved in Endomembrane System, Protein<br>Folding and Ubiquitin-Mediated Proteolysis in Hippocampus<br>Following Sarin Treatment ..... | 27          |
| Table 13: Perturbation of Signaling Pathways in Hippocampus after Sarin Treatment .....                                                                                     | 27          |
| Table 14: Perturbation of Pathways Involved in DNA Damage/Repair,<br>Glutathione Metabolism, Apoptosis and Tissue Repair in<br>Hippocampus Following Sarin Treatment .....  | 28          |
| Table 15: Perturbation of Pathways Involved in Neuronal Growth and Differentiation in<br>Hippocampus Following Sarin Treatment .....                                        | 29          |
| Table 16: Perturbation of Pathways Involved in Neuron Projection, Axonal, Dendritic<br>And Synaptic Structure in Hippocampus Following Sarin Treatment .....                | 30          |
| Table 17: Perturbation of Pathways Involved in Synaptic Transmission and Synaptic<br>Plasticity in Hippocampus Following Sarin Treatment .....                              | 31          |

|                                                                                                                                                                |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Table 18: Perturbation of Pathways Involved in Behavioral/Cognitive Functions and<br>Neurodegenerative Diseases in Hippocampus Following Sarin Treatment ..... | 32 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----|

## PREFACE

This research was conducted at the Molecular Bioeffects Branch (RHDJ), Human Effectiveness Directorate, 711th Human Performance Wing, Air Force Research Laboratory, Wright-Patterson AFB OH, under Dr. John J. Schlager, Branch Chief. This technical report was written as the Final Report for AFRL Work Unit ODTWP001. This project was funded by Defense Threats Reduction Agency (DTRA).

Employees of Henry M. Jackson Foundation (HJF) were working under the Cooperative Agreement FA8650-05-2-6518 between RHDJ and HJF. Animal exposure was conducted at Wright State University (WSU) under the HJF Cooperative Agreement FA8650-05-2-6518, Subaward # 667357.

All studies involving animals were approved by the WSU Institutional Animal Care and Use Committee (IACUC) on 11 August 2009, and by the Wright-Patterson IACUC on 29 September 2009. All procedures involving live animals were conducted in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International, in accordance with the *Guide for the Care and Use of Laboratory Animals*, National Research Council (1996). All experiments were conducted according to the Animal Use Protocol AUP #810 “*Organ Specific Perturbation of Biological Pathways and Processes Resulted from Exposure to Organophosphorus Agent in Mice (Mus musculus)*”.

## **ACKNOWLEDGEMENTS**

The authors would also like to thank Dr. James Lucot and Ms. Teresa Garrett for conducting the animal study, which is under the HJF Cooperative Agreement FA8650-05-2-6518, Subaward # 667357. This project was funded by Defense Threats Reduction Agency (DTRA).

## SUMMARY

This project aimed to investigate the molecular mechanism(s) of organ injury following exposure to sublethal doses of the organophosphorus agent, sarin. The lethal toxic effect of sarin exposure is caused by irreversible inhibition of acetylcholinesterase (AChE) and subsequently excessive stimulation of postsynaptic cholinergic receptors. However, much less is known about the effects of low-dose sarin exposure on functions of critical brain regions. Neurotoxicity caused by sarin exposure can be mediated by pathways independent of the cholinergic system. Sarin exposure, even at non-convulsive and clinically asymptomatic doses, can induce prolonged adverse effects on cognitive and neurobehavioral functions in animal models. Consistent to these observations, sarin exposure resulted in cognitive deficits in the survivors of the sarin attacks in Japan. Rescue workers and victims, who did not develop any symptoms of acute cholinergic neurotoxicity, also exhibited chronic decline in memory. Since the hippocampus plays an important role in cognitive functions (including learning and memory), and is one of the most sensitive brain regions to sarin-induced injury, the focus of this study is to investigate differential gene expression and pathway perturbation in this brain region, using microarray technology combined with advanced bioinformatics. The results of functional observational battery (FOB) assessment revealed that sarin treatment, at 0.4x and 0.6x Mean Lethal Dose (LD50), were asymptomatic (or minimally symptomatic). However, ~60% of the animals treated with the dose of 0.75x LD50 had seizure. In contrast to the FOB result, sarin treatment, at 0.6x LD50, resulted in significant inhibition of AChE in the frontal lobe, especially at 2-6 hours after the treatment. As expected, a larger degree of AChE inhibition was observed with 0.75x LD50. Sarin treatment resulted in differential expression of a large number of genes. Most of these genes showed increased expression, especially at the 6-hour and 25-day time points. However, significant gene repression was observed at the 10-day time point. Pathway analysis revealed that one of the direct effects of sarin cellular toxicity could be related to DNA damage and inhibition of the glutathione antioxidant system, which triggered the up-regulation of the apoptotic pathways at early time points. To re-establish the homeostatic state, transcription, mRNA processing and splicing, translation and post-translation modifications were subsequently activated. The genes being up-regulated are involved in signaling pathways (both cell-cell signaling and intracellular signaling), cell proliferation (including neurogenesis), neuron differentiation, neuron projection development, axonogenesis, dendritic development, synaptogenesis, synaptic transmission, synaptic plasticity and behavioral/cognitive functions. However, processing of the newly synthesized proteins (such as protein folding and protein transport) appeared to be dysregulated, as the genes essential for components of the endomembrane system, including endoplasmic reticulum (ER) and Golgi apparatus were significantly down-regulated. As a result of dysfunction of endomembrane system, the ER stress response (including unfolded protein response and ER overload response) were up-regulated, which in turn induced the up-regulation of the apoptotic pathways at the subsequent time points. This finding is likely a participating event of the known sarin-induced delayed neurotoxicity.

**Keywords:** organophosphorus agent, sarin, acetylcholinesterase, DNA microarray, advanced bioinformatics, differential gene expression, pathway perturbation, unfolded protein response, endoplasmic reticulum (ER) overload, ER stress

**Technical Report:** January 2012

## 1. INTRODUCTION

### 1.1 Toxicity of Sarin Exposure

Sarin elicits its acute lethal toxic effects in large part by irreversible inhibition of AChE, resulting in excessive stimulation of postsynaptic cholinergic receptors. The clinical sequelae following high-dose sarin exposure include tremors, muscle fasciculation, salivation, seizure, respiratory depression, coma, and death. Animal studies have provided rich data on the acute toxic consequence and sequelae progression following high-dose exposure. However, much less is known about the effects, especially the long-term toxic effects, of low-dose sarin exposure on functions of critical brain regions and major peripheral organs. In addition to its cholinergic effects, there is evidence that neurotoxicity caused by sarin exposure can be mediated by pathways independent of the cholinergic system (Fernando et al, 1985; Rickett et al, 1986; Kadar et al, 1995).

In addition to its neurotoxic effects, sarin exposure may also result in injury of multiple vital organs, including heart, liver, kidney, bladder and adrenal gland via poorly understood mechanisms (Singer et al, 1987; Anzueto et al, 1990; Pant et al, 1993; Allon et al, 2005; Shih et al, 2006; Yanagisawa et al, 2006; Bloch-Shilderman & Levy, 2007; Morris et al, 2007). While sublethal doses of sarin do not result in acute overt toxicity, they have been shown to produce delayed damage and/or functional deficits in multiple vital organs. As exposure to low-level chemical warfare agents including sarin has become a world-wide emerging threat to military and civilian populations, it is therefore essential to elucidate the molecular mechanisms of sarin-induced organ injury.

Sarin exposure evidence has shown that even at non-convulsive and clinically asymptomatic dose, prolonged adverse effects can occur causing cognitive and neurobehavioral dysfunctions in a dose-dependent manner (Landauer et al, 1984; Kassa et al, 2001a; Kassa et al, 2001b; Kassa et al, 2001c; Kassa et al, 2002; Kassa et al, 2004; Genovese et al, 2008). A similar effect of sarin treatment on cognitive functions has also been observed in guinea pigs and nonhuman primates (Hulet et al, 2002; Genovese et al, 2007). Grauer et al (2008) reported that rats exposed to sarin resulted in long-lasting impairment of working and reference memory processes with no recovery observed during the study. Animals that seem to fully recover from the exposure, as well as the animals that initially show no toxic signs, developed neural changes indicative of neuronal inflammation lasting up to several months following exposure. Mice exposed to asymptomatic doses display long-lasting deficiency in emotional learning due to a region-specific impairment in dopaminergic functions (Lucot JB, personal communication). Interestingly, data on sarin exposures have shown inhibition of new memory formation rather than a degraded memory retrieval process. These observations are consistent with the findings of sarin-induced cognitive and performance deficits in the survivors of the sarin attacks in Japan (Hatta et al., 1996; Yokoyama et al. 1998). Rescue workers and victims, who did not develop any symptoms of acute cholinergic neurotoxicity, also exhibited chronic decline in memory (Nishiwaki et al, 2001; Miyaki et al, 2005).

## **1.2 Mechanistic Analysis of Sarin-Induced Organ Injury**

Given the complexity of cellular response to the toxicity of sarin exposure, a global profiling of the changes in the cellular constituents will be needed in order to elucidate the molecular events following sarin exposure. This approach could significantly facilitate the understanding of the molecular mechanism of sarin-induced organ injury. In addition, it could also facilitate the identification of biomarkers for early detection of the early events of sarin-induced injury. Ultimately, it could guide the development of countermeasures that can effectively treat and/or prevent the onset of organ injury induced by sarin and other organophosphorus (OP) agents.

Of different -omics technologies, DNA microarray technology is the most powerful profiling technique with the promise of global coverage. Using this technique, previous reports from this laboratory have shown successes in assessing differential gene expression and pathway modulation in response to a toxic insult (Soto et al, 2008; Stapleton et al, 2009; Davidson et al, 2009). Detailed analysis of the patterns of differential gene expression at different time points can reveal temporal progression of cellular events associated with initial defensive response, cellular damage/organ injury, and tissue repair/remodeling. These data, in turn, will provide novel mechanistic insights into the initiation, progression, and persistence of molecular lesions that lead to cellular/tissue pathology and functional deficits in the organs under study.

Although studies addressing different aspects of low-dose sarin (or other OP) treatments have previously been performed using various animal models (Kassa et al, 2001a; Kassa et al, 2001b; Henderson et al, 2002; Hulet et al, 2002; Kassa et al, 2002; Shih et al, 2006; Genovese et al, 2008), studies specifically designed for the investigation of the molecular mechanism(s) of injury in multiple brain regions and multiple vital organs following exposure to sublethal doses of sarin have not been conducted. To address this knowledge gap, a systematic and comprehensive investigation of differential gene expression using DNA microarrays in multiple brain regions and multiple vital organs was proposed, funded by the Defense Threat Reduction Agency (DTRA), and initiated by the AF. A number of brain regions and major peripheral organs from sarin-treated animals were isolated and preserved. These tissues would be invaluable for a comprehensive investigation of sarin-induced differential gene expression and pathway perturbation, which will likely provide novel insights into the underlying mechanisms of sarin-induced organ injury. Integration of pathway perturbation results within these brain regions and peripheral organs will provide an understanding of the molecular mechanism of sarin-induced injury at the organism level. These data will address the initial molecular and mechanistic foundation. This in turn will significantly facilitate future development of pre-exposure and/or post-exposure countermeasures that can prevent and treat overall injury induced by sarin and other OP agents.

## **1.3 Molecular Mechanism of Sarin-Induced Hippocampal Injury**

The brain hippocampus plays an important role in cognitive function(s), including learning and memory (especially spatial memory and the transference of short-term to long-term memory). Hippocampus is also one of the most sensitive brain regions to sarin-induced injury. Because of these reasons, the initial focus of this study is to investigate differential gene expression and pathway perturbation in this brain region. Specifically, differential gene expression in the hippocampal region following sarin exposure was investigated using DNA microarrays in a

mouse model. The DNA microarray data was analyzed to elucidate the molecular mechanism of sarin-induced injury by the analysis of perturbation of biological pathways using advanced bioinformatics. These results as described will provide novel insights into the molecular mechanism(s) of sarin-induced hippocampal injury, as well as the mechanism(s) of sarin-induced cognitive performance degradation as observed in animal studies and in humans (Landauer et al, 1984; Kassa et al, 2001a; Kassa et al, 2001b; Kassa et al, 2001c; Nishiwaki et al, 2001; Hulet et al, 2002; Kassa et al, 2002; Kassa et al, 2004; Miyaki et al, 2005; Genovese et al, 2007; Genovese et al, 2008; Grauer et al, 2008).

## **2. MATERIALS AND METHODS**

Animal exposure was conducted at Wright State University (WSU) under the Henry M. Jackson Foundation Cooperative Agreement FA8650-05-2-6518, Subaward # 667357. All procedures involving live animals were conducted in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International, in accordance with the Guide for the Care and Use of Laboratory Animals, National Research Council (1996). All experiments were performed according to the Animal Use Protocol AUP #810 “*Organ Specific Perturbation of Biological Pathways and Processes Resulted from Exposure to Organophosphorus Agent in Mice (Mus musculus)*”. This animal protocol was approved by the WSU Institutional Animal Care and Use Committee (IACUC) on 11 August 2009. It was subsequently reviewed and approved by the Wright-Patterson IACUC on September 29, 2009.

### **2.1 General Procedures**

Male Swiss Webster mice (body weight 26–28 g, aged 3 months) (from Harlan Lab.) were kept in a temperature-controlled room (21–23 °C) with a 12-h light/dark and provided with standard diet (Mouse Chow 5015, from Purina, St. Louis, MO) and tap water *ad libitum*. Treatment of animals with sarin was carried out in the Dilute Chemical Surety Facility at Wright State University, which is approved for handling sarin.

### **2.2 Determination of Mean Lethal Dose (LD50) for Sarin**

Since the potency of each batch of sarin received from USAMRICD is different, the LD50 of each of the batches of sarin used in this study were determined experimentally. Groups of 10 animals received a single dose of sarin subcutaneously (s.c.) with concentrations starting with the LD50 calculated from historical data and the concentration determined by USAMRICD (i.e. 275–390 µg/kg). Additional concentrations up to plus or minus 10% the LD50 were also used. A 24-hr lethality time point was used to establish the LD50. The surviving animals were sacrificed at the end of the experiment.

### **2.3 Treatment of Animals with 0.4x, 0.6x and 0.75x LD50 of Sarin**


For the studies of sarin-induced differential gene expression and pathway perturbation, three doses (0.4x, 0.6x and 0.75x LD50) of sarin, matched with vehicle controls, were administered via s.c. injection. The control and sarin-treated animals were monitored using a functional observational battery (FOB) for signs of treatment-related toxicity, and scores recorded. Since five surviving animals per group are needed for the analysis of differential gene expression, the

group sizes for the doses of 0.6x and 0.75x LD<sub>50</sub> were increased to six and eight animals per group, respectively. This is to account for the possibility that some of the animals will be lost prior to the 24 hr experimental endpoint, due to treatment-induced mortality. Sarin-induced differential gene expression at eight time points, 2 hours, 6 hours, 12 hours, 1 day, 2 days, 5 days, 10 days and 25 days post-treatment, was investigated. Table 1 shows the number of animals in each of the sample groups with respect to sarin doses and time points after sarin injection.

**Table 1: Number of Animals in Each Treatment Group\***

| Time Point (hours after sarin injection) | Sarin (GB) Dose (xLD <sub>50</sub> ) |     |     |      |
|------------------------------------------|--------------------------------------|-----|-----|------|
|                                          | 0                                    | 0.4 | 0.6 | 0.75 |
| 0                                        | 5                                    | 0   | 0   | 0    |
| 2                                        | 5                                    | 5   | 6   | 8    |
| 6                                        | 5                                    | 5   | 6   | 8    |
| 12                                       | 5                                    | 5   | 6   | 8    |
| 24                                       | 5                                    | 5   | 6   | 8    |
| 28                                       | 5                                    | 5   | 6   | 8    |
| 120                                      | 5                                    | 5   | 6   | 8    |
| 240                                      | 5                                    | 5   | 6   | 8    |
| 600                                      | 5                                    | 5   | 6   | 8    |
| Total (8 Time points)                    | 45                                   | 40  | 48  | 64   |

\*Each animal group represents a specific combination of dose and time point.



**Figure 1: Diagram of Overall Study Design.** The time points of FOB evaluation, tissues collection and AChE/BuChE activity assays are illustrated. Brain regions and peripheral organs collected are listed.

Six brain regions (hippocampus, frontal lobe, thalamus, piriform cortex, amygdala and cerebellum) and six peripheral organs (heart, liver, kidney, bladder, lung and adrenal gland) were collected, processed as required and snap-frozen in liquid nitrogen. The frozen tissues were preserved at -80 °C for long-term storage until processing for the analysis of AChE and butyrylcholinesterase (BuChE) inhibition and RNA extraction. The whole blood collected from each animal was split into two halves, one for the isolation of plasma and peripheral blood mononucleated cells for long-term storage at -80 °C, while the other half was used for measuring AChE and BuChE activities. The overall design of this study is shown in Figure 1.

## 2.4 Evaluation of Sarin-Induced Toxicity

Sarin-induced toxicity was evaluated using two methods:

- Non-invasive FOB Scoring System; and
- Inhibition of AChE and BuChE in frontal lobe and plasma/red blood cells.

### 2.4.1 FOB Assessment

Noninvasive FOB assessment is a checklist of symptoms associated with OP exposure. Signs of behavioral functions of control and sarin-treated animals were directly observed through the housing cage. Handling was eliminated as it is a stressor to the animals that confounds results. The functional categories under observation were autonomic, neuromuscular, and convulsive. Autonomic parameters included eye closure and breathing status. Neuromuscular parameters are primarily postural and gait. These included flattened posture, lying on side, prostrated, and staggering. Convulsive parameters included tail waving, tremors, and convulsions or seizures. The FOB scores were taken at 4 time points (0.5, 1, 4 and 24 hours) after sarin injection. The maximum FOB score is 21 (severely affected by sarin treatment and/or death), while that of an animal showing normal behavioral functions is 6. Additionally, the time of first seizure and the time of death, if occurred, were also recorded. In the case that the death of an animal occurs before any symptoms can be observed, a maximum score of 21 points will be assigned. An example of a FOB Scoring Worksheet is shown in Table 2.

**Table 2: FOB Scoring System Worksheet**

| Behavioral Functions          | Score    |                            |                   |                            |
|-------------------------------|----------|----------------------------|-------------------|----------------------------|
|                               | 1        | 2                          | 3                 | 4                          |
| Posture                       | normal   | flattened                  | prostration       | side / contorted / splayed |
| Motor Behavior                | normal   | tail twitching / hypo-loco | tremors           | convulsions                |
| Gait Score                    | normal   | staggering / splayed       | severe staggering | unable to move             |
| Eyelid                        | open     | half closed                | slight protrusion | severe protrusion          |
| Breathing                     | open     | fast shallow               | slow labored      |                            |
| Death                         | no death | death                      |                   |                            |
| <b>Additional Information</b> |          |                            |                   |                            |
| Body Temp                     |          |                            |                   |                            |
| Time of first Seizure         |          |                            |                   |                            |
| Time of death                 |          |                            |                   |                            |
| Other Comments                |          |                            |                   |                            |

### **2.4.2 Inhibition of AChE and BuChE**

To evaluate treatment-induced toxicity, AChE and BuChE activities in frontal cortex and blood were analyzed. Frozen brain tissue were homogenized in a buffer (containing 0.1 M sodium phosphate buffer, pH 7.4, and 0.5 % Tween 20) and centrifuged at 13,000 xg for 5 min. Tissue extracts were recovered, and AChE and BuChE activities analyzed according to the Ellman method (Ellman et al., 1961). Additionally, the erythrocyte AChE activity and plasma BuChE activity were determined using the trunk blood collected at the time of sacrifice. Five microliters ( $\mu$ L) of tissue extract or blood was added to the reaction buffer. For each sample, half of each replicate was treated with tetraisopropylpyrophosphoramidate (iso-OMPA) to determine the relative activity of AChE (iso-OMPA selectively inhibits BuChE activity). The relative activity of BuChE was determined by subtracting the AChE activity (reaction with iso-OMPA) from the total activity (reaction without iso-OMPA).

The statistical software “R” (version 2.6.2) was used for statistical analysis and graphical presentation of the results of AChE and BuChE activity assays. In general, analysis of variance (ANOVA) was used for data showing a Gaussian distribution. The statistical significance threshold was set at 0.05.

### **2.5 Collection and Processing Tissue Samples**

At eight specific time points (i.e., 2 hours, 6 hours, 12 hours, 1 day, 2 days, 5 days, 10 days and 25 days) after sarin treatment, the control and sarin-treated animals were sacrificed. The brain collected from each animal was washed thoroughly with ice-cold RNase-free water to remove traces of blood, split into two portions, one for AChE activity measurement and the other for gene expression profiling. The half for gene expression was immediately immersed in RNAlater (Ambion, USA) at 4 °C to stabilize the transcriptome prior to further dissection to isolate specific brain regions (hippocampus, frontal lobe, thalamus, piriform cortex, amygdala and cerebellum). The dissected brain tissues were preserved at -80 °C until processing for total RNA extraction. Other peripheral organs (heart, liver, kidney, bladder, lung and adrenal gland) were also collected, processed and preserved in a similar manner at the time of necropsy. The portion for AChE/BuChE activity measurement was processed immediately to isolate the frontal lobe, which is then snap-frozen in liquid nitrogen and stored at -80°C.

Blood samples were collected, and split into two equal portions. Erythrocytes, leukocytes and plasma were separated by differential centrifugation using one half of the blood sample. The erythrocytes, leukocytes and plasma were then recovered, snap-frozen and preserved at -80°C. The other half of the blood sample that is for AChE/BuChE activity assay was snap-frozen in liquid nitrogen and stored at -80°C.

### **2.6 Transcriptomic Profiling of Hippocampal Region**

Although several brain regions and peripheral organs were collected from the animals, only the hippocampal region was used for transcriptomic profiling in this initial effort. Transcriptomic profiling was performed using the Affymetrix Mouse Exon 1.0 ST GeneChip Arrays. Total RNA was isolated from the hippocampal tissues using Qiagen RNeasy Mini Kit (Qiagen,

Valencia, CA). Frozen tissues were homogenized in lysis buffer containing guanidinium thiocyanate and  $\beta$ -mercaptoethanol. Extraction and purification of total RNA from tissue homogenates were performed according to the manufacturer's instructions. The quality of the isolated RNA was confirmed using the RNA 6000 Nano LabChip Kit with the Agilent 2100 Bioanalyzer System (Agilent Biotechnologies, Palo Alto, CA). RNA concentration was determined using the NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE).

The purified total RNAs were used for target preparation as described in the user manuals for whole transcript (WT) expression analysis (Ambion WT Expression Kit and Affymetrix GeneChip WT Expression Array Kit). Briefly, 50 ng total RNA was used for first-strand cDNA synthesis in the presence of oligo (dT)-T7 promoter primers. The resulting first-strand cDNA was then converted to double-stranded cDNA, which was then used as template for *in vitro* transcription. The synthesized cRNA was purified by binding to magnetic Nucleic Acid Binding Beads, followed by several washes in isopropanol and Nucleic Acid Wash Solution. The cRNA was then eluted using elution solution preheated to 56 °C. The purified cRNA was then used for the second round of cDNA synthesis in the presence of random primers. After the cDNA synthesis was completed, the cRNA template was removed by RNase H digestion. The resulting single-stranded cDNA was purified using the magnetic Nucleic Acid Binding Beads as described above. The purified single-stranded cDNA was fragmented to reduce its size. The fragmented cDNA was purified using the Affymetrix Sample Clean-Up Module Kit. The purified single-stranded cDNA was then labeled with biotin using Terminal deoxynucleotidyl transferase. The biotin-labeled cDNA was purified using the Affymetrix Clean-Up Module Kit. The concentration and purity of each labeled cDNA sample were determined by measuring  $A_{260}$  and the ratio of  $A_{260}/A_{280}$ , respectively.

Hybridization cocktail, which contained (for each sample) 5.5  $\mu$ g of labeled cDNA, Affymetrix control oligo B2, Affymetrix eukaryotic hybridization control, herring sperm DNA, acetylated BSA and dimethyl sulfoxide in 1x hybridization buffer (final concentration) was heated to 99 °C for 5 min, then cooled to 45 °C for 5 min before being loaded onto an Affymetrix Mouse Exon 1.0 ST GeneChip array. Hybridization was performed at 45 °C for 16 hours in an Affymetrix hybridization oven with constant end-over-end rotation at 60 RPM. Once hybridization was complete, hybridization mix was removed from each GeneChip array, and the microarrays washed and stained in the Affymetrix Gene-Chip Fluidics Station 450 using the EukGE\_Ws2v5 protocol. After washing and staining, the microarrays were scanned in the Affymetrix GeneChip Scanner 3000 using the Affymetrix GeneChip Command Console Software (AGCC) software. The scanned images were stored as .dat files. Data obtained from the Affymetrix GeneChip Scanner 3000 were then processed using the Affymetrix Expression Console Software for quality control analysis. Only the microarrays that passed the quality control test were included in the down-stream data analysis.

## **2.7 Identification of Sarin-Induced Hippocampal Gene Expression Changes and Pathway Perturbation**

To identify sarin-induced hippocampal gene expression changes, the data files were exported from the Affymetrix Expression Console and imported into the Biotique XRAY software.

Statistical analysis of significant gene expression changes was performed using sarin treatment as the study factor with the significance threshold set at 0.05. The option of all pair-wise comparison was selected to identify significant gene expression changes between the control and all dose groups, as well as that among all dose groups. Multiple test correction was implemented using the Holm's Step-down Bonferroni Method (Holm, 1979). The “extended probe sets” filter, which includes transcript clusters supported by RefSeq, Ensembl Transcripts, full-length mRNAs, cDNA-based annotations and other genomic annotations of medium reliability, was used. This filter provided a total of ~129,000 transcripts (including alternatively spliced products). To ensure data quality, probe sets with a GC count <6 or >17, as well as that with <3 probes per probe set, were excluded from the analysis. Non-expressed probe sets (signals <10% above background or detection significance threshold >0.05) were also excluded. Finally, a fold change threshold >1.2 was implemented.

To group the differentially expressed genes with a similar dose- or temporal response pattern in terms of expression changes, the differentially expressed genes were subjected to self-organizing map (SOM) clustering analysis. In addition, the lists differentially expressed genes were exported as text files for pathway analysis and biological interpretation. Finally, to identify pathways with statistically significant gene enrichment ( $p < 0.05$ ), the lists of up- and down-regulated genes, as well as the list of all differentially expressed genes, were used as input files to search the biological annotation databases (e.g. the Gene Ontology and the KEGG pathway databases) in the Database for Annotation, Visualization, and Integrated Discovery (DAVID) website (Huang et al, 2007).

### **3. RESULTS**

#### **3.1 Sarin-Induced Toxicity**

##### **3.1.1 FOB Assessment**

In this study, mice were treated by subcutaneous injection with sublethal doses of sarin ranging from 0.4x – 0.75x LD50. For logistic reasons, each time point was conducted as an independent experiment (see Table 1 for details). Of all sarin-treated animals, only 1 animal died. However, 38 animals (~60%) receiving sarin treatment at the dose of 0.75x LD50 had seizure, with >80% of these events occurring within 20 minutes after sarin injection. Table 3 shows the time of first seizure occurrence in the animals that were positive for sarin-induced seizure.




Other symptoms associated with OP exposure were also evaluated using the FOB scoring system. The functional categories under observation were autonomic parameters (including eye closure and breathing status), neuromuscular parameters (primarily postural and gait including flattened posture, lying on side, prostrated, and staggering), convulsive parameters (including tail waving, tremors, convulsions and seizures). As shown in Figure 2 (see Supplemental Table 1 for detailed scores), animals with sarin treatment at 0.4x and 0.6x LD50 were mostly asymptomatic or minimally symptomatic, while animals treated with 0.75x LD50 showed symptoms characteristic of OP exposure with statistically significant increases in FOB scores, especially at early time points up to 4 hours post-treatment. Most of these symptoms emerged within 30 minutes after sarin treatment and maintained at the peak level within the first hour. However, the


animals showed some degree of recovery at 4 hours post-treatment. By 24 hours, almost all animals showed complete recovery from sarin-induced toxicity, with respect to FOB scores.

**Table 3: Percentage of Animals with Seizure and Time of First Seizure Occurrence in the 0.75x LD50 Dose Group at Each Time Point.**

| Sacrifice Time Point (post-injection) | Animal | Time of first seizure (m:s) | % with Seizure |
|---------------------------------------|--------|-----------------------------|----------------|
| 2 Hr                                  | 1      | 6:01                        | 62.5%          |
|                                       | 2*     | 7:07                        |                |
|                                       | 3      | 13:05                       |                |
|                                       | 4      | 16:16                       |                |
|                                       | 5      | 17:16                       |                |
| 6 Hr                                  | 1      | 11:27                       | 37.5%          |
|                                       | 2      | 16:37                       |                |
|                                       | 3      | 20:03                       |                |
| 12 Hr                                 | 1      | 1:29                        | 37.5%          |
|                                       | 2      | 1:33                        |                |
|                                       | 3      | 1:40                        |                |
| 24 Hr                                 | 1      | 9:50                        | 50.0%          |
|                                       | 2      | 10:57                       |                |
|                                       | 3      | 12:54                       |                |
|                                       | 4      | 19:09                       |                |
| 2 Days                                | 1      | 10:06                       | 75.0%          |
|                                       | 2      | 11:39                       |                |
|                                       | 3      | 14:50                       |                |
|                                       | 4      | 19:25                       |                |
|                                       | 5      | 26:52                       |                |
|                                       | 6      | 52:42                       |                |
| 5 Days                                | 1      | 11:03                       | 50.0%          |
|                                       | 2      | 11:05                       |                |
|                                       | 3      | 11:08                       |                |
|                                       | 4      | 25:30                       |                |
| 10 Days                               | 1      | 8:04                        | 100.0%         |
|                                       | 2      | 9:11                        |                |
|                                       | 3      | 10:17                       |                |
|                                       | 4      | 13:00                       |                |
|                                       | 5      | 13:03                       |                |
|                                       | 6      | 14:26                       |                |
|                                       | 7      | 14:38                       |                |
|                                       | 8      | 17:10                       |                |
| 25 Days                               | 1      | 10:51                       | 62.5%          |
|                                       | 2      | 11:10                       |                |
|                                       | 3      | 16:07                       |                |
|                                       | 4      | 16:15                       |                |
|                                       | 5      | 38:42                       |                |

\*Treatment-induced mortality was observed.






**Figure 2: FOB Scores of Control and Sarin-treated Animals.** The control and treated animals were monitored at 4 time points after sarin treatment and scored according to the FOB Scoring System as described above. (A) Animals were observed at 30 minutes post-treatment; data of three experiments, 2-hr, 6-hr and 24-hr time points, is not available. (B) Animals were observed at 1 hour post-treatment; data of the 12-hr time point experiment is not available. (C) Animals were observed at 4 hour post-treatment; animals of the 2-hr time point experiment have been sacrificed. (D) Animals were observed at 24 hour post-treatment; animals of the experiments for the first four time points (i.e., 2, 6, 12 and 24 hours) have been sacrificed. X-axis = time points at which animals were sacrificed. Y-axis = average percentage of maximum score (21 points). Error bar = standard error. \* = Significant difference ( $p < 0.05$ ).


### 3.2 Sarin-Induced Toxicity - Inhibition of AChE and BuChE

Sarin-induced toxicity was also assessed by inhibition of AChE and BuChE in the frontal lobe. Consistent with the FOB results, sarin treatment at 0.4x LD50 did not result in significant changes in AChE activity, except that a few cases showed statistically significant (but small) inhibition of AChE (Figure 3). Although sarin treatment at 0.6x LD50 resulted in minimal changes in behavioral functions, significant inhibition (i.e. ~50%) of AChE (and BuChE) was observed, especially within the first 6 hours after treatment. Significant inhibition of AChE, at ~35%, persisted up to 10 days post-treatment. Even at 25 days after sarin treatment, ~20% inhibition of AChE could still be observed. However, the changes at the late time points did not reach statistical significance. As expected, sarin treatment at 0.75x LD50 resulted in dramatic inhibition (>60%) of AChE (and BuChE) in the frontal lobe (for details, see Supplemental Table 2).



**Figure 3: Frontal Lobe AChE and BuChE Activities.** AChE activity was determined using the Ellman Method (Ellman et al., 1961). Statistically significant inhibition of AChE in the 0.6x and 0.75x LD50 dose groups was observed up to 5 days post-treatment. (A) AChE activity. (B) BuChE activity. X-axis = time points after sarin treatment. Y-axis = Enzyme activity (nmoles/min/μL). Error bar = standard error. \* = Significant inhibition ( $p < 0.05$ ) of AChE and BuChE.


Inhibition of AChE and BuChE in the blood was also determined. In contrast to the FOB and frontal lobe AChE results, sarin treatment at 0.4x LD50 resulted in significant inhibition ( $\geq 50\%$ ) of erythrocyte AChE up to 12 hours (Figure 4). However, the enzyme activity recovered at later time points. Similarly, sarin treatment resulted in significant inhibition of plasma BuChE in all doses at 2 hours post treatment, which is followed by a rapid recovery of the enzyme activity. Blood AChE and BuChE activities in control and sarin-treated animals are shown in Supplemental Table 3.



**Figure 4: Blood AChE and BuChE Activities.** AChE activity was determined using the Ellman Method (Ellman et al., 1961). Statistically significant inhibition of erythrocyte AChE in the sarin treatment groups was observed up to 12 hours post-treatment. (A) Erythrocyte AChE activity. (B) Plasma BuChE activity. X-axis = time points after sarin treatment. Y-axis = Enzyme activity (nmoles/min/ $\mu$ L). Error bar = standard error. \* = Significant inhibition ( $p < 0.05$ ) of AChE and BuChE.

### 3.3 Sarin-Induced Hippocampal Gene Expression Changes

Statistical analysis of the microarray data revealed that sarin treatment resulted in differential expression of a large number of genes (Figure 5 and Supplemental Table 4).



**Figure 5: Sarin-Induced Hippocampal Differential Gene Expression.** The number of up- and down-regulated genes in the hippocampal region following sarin treatment is shown.

### 3.3.1 Dose Response of Hippocampal Gene Expression Following Sarin Treatment

The dose response of the differentially expressed genes at each time points is determined using the SOM clustering analysis, an unsupervised pattern recognition technique, with a 3x3 setting to generate nine clusters. The results are summarized in Tables 4, A-H (the SOMs at these time points are shown in Supplemental Figure 1, A-H).

**Table 4: Dose Response of Sarin-Induced Hippocampal Differential Gene Expression.** The result of SOM clustering analysis revealed that the differentially expressed genes showed unique dose response patterns after sarin treatment. The result at each time point is shown separately.

| A. 2 Hours Post-treatment |           |                    |                    |         |     |                  |       |          |                    |
|---------------------------|-----------|--------------------|--------------------|---------|-----|------------------|-------|----------|--------------------|
| Cluster #                 | 0.4xLD50  | 0.6xLD50           | 0.75xLD50          | # Genes |     | Dose Response    | Total | Trend    | Pattern            |
| Cluster 1                 | Up        | Same as 0.4xLD50   | Up more            | 150     | 163 | 0.4=0.6 < 0.75   | 163   | Up       | Highest: 0.75xLD50 |
| Cluster 4                 | Up        | Same as 0.4xLD50   | Up more            | 13      |     |                  |       |          |                    |
| Cluster 2                 | Up        | Less than 0.4xLD50 | Less than 0.4xLD50 | 49      | 49  | 0.4 > 0.6=0.75   | 80    | Up       | Highest: 0.4xLD50  |
| Cluster 3                 | Up        | No change          | No change          | 31      | 31  | 0.4 > 0.6=0.75   |       |          |                    |
| Cluster 6                 | Up        | Down               | Down more          | 17      | 17  | 0.4 > 0.6=0.75   | 17    | Variable | Highest: 0.4xLD50  |
| Cluster 7                 | No change | Up                 | Up more            | 31      | 31  | 0.4 < 0.6 < 0.75 | 31    | Up       | Progressively up   |
| Cluster 8                 | Down      | No change          | No change          | 4       | 4   | 0.4 < 0.6=0.75   | 4     | Down     | 0.4xLD50 only      |
| Cluster 9                 | Down      | Same as 0.4xLD50   | Same as 0.4xLD50   | 109     | 109 | 0.4 = 0.6 = 0.75 | 109   | Down     | Dose independent   |
| Cluster 5                 | N/A       | N/A                | N/A                | 0       | 0   | N/A              | 0     | N/A      | N/A                |

| B. 6 Hours Post-treatment |          |                  |           |         |     |                |       |       |                    |
|---------------------------|----------|------------------|-----------|---------|-----|----------------|-------|-------|--------------------|
| Cluster #                 | 0.4xLD50 | 0.6xLD50         | 0.75xLD50 | # Genes |     | Dose Response  | Total | Trend | Pattern            |
| Cluster 1                 | Up       | Same as 0.4xLD50 | Up more   | 124     | 156 | 0.4=0.6 < 0.75 | 156   | Up    | Highest: 0.75xLD50 |
| Cluster 5                 | Up       | Same as 0.4xLD50 | Up more   | 32      |     |                |       |       |                    |

|           |           |                    |                  |     |      |                  |      |          |                   |
|-----------|-----------|--------------------|------------------|-----|------|------------------|------|----------|-------------------|
| Cluster 8 | Up        | More than 0.4xLD50 | Same as 0.4xLD50 | 202 | 438  | 0.4=0.75 < 0.6   | 438  | Up       | Bell-shaped       |
| Cluster 9 | Up        | More than 0.4xLD50 | Same as 0.4xLD50 | 236 |      |                  |      |          |                   |
| Cluster 2 | Up        | Less than 0.4xLD50 | Same as 0.4xLD50 | 251 | 1050 | 0.4=0.75 > 0.6   | 1050 | Up       | U-shaped          |
| Cluster 3 | Up        | Less than 0.4xLD50 | Same as 0.4xLD50 | 370 |      |                  |      |          |                   |
| Cluster 6 | Up        | Less than 0.4xLD50 | Same as 0.4xLD50 | 429 |      |                  |      |          |                   |
| Cluster 4 | Up        | Less than 0.4xLD50 | Same as 0.6xLD50 | 7   | 7    | 0.4 > 0.6=0.75   | 7    | Up       | Highest: 0.4xLD50 |
| Cluster 7 | No change | Up                 | Down             | 437 | 437  | 0.6 < 0.4 < 0.75 | 437  | Variable | Up then down      |

| C. 12 Hours Post-treatment |           |                  |                  |         |     |                  |       |          |                      |
|----------------------------|-----------|------------------|------------------|---------|-----|------------------|-------|----------|----------------------|
| Cluster #                  | 0.4xLD50  | 0.6xLD50         | 0.75xLD50        | # Genes |     | Dose Response    | Total | Trend    | Pattern              |
| Cluster 6                  | Up        | Same as 0.4xLD50 | Up more          | 423     | 423 | 0.4=0.6 < 0.75   | 423   | Up       | Highest: 0.75xLD50   |
| Cluster 5                  | Up        | No change        | No change        | 1       | 1   | 0.4 > 0.6=0.75   | 1     | Up       | 0.4xLD50 only        |
| Cluster 7                  | Down      | Down more        | Same as 0.6xLD50 | 529     | 529 | 0.4 > 0.6=0.75   | 529   | Down     | Highest: 0.4xLD50    |
| Cluster 3                  | Up        | Down             | Up               | 37      | 37  | 0.4=0.75 > 0.6   | 112   | Variable | U-shaped             |
| Cluster 2                  | No change | Down             | No change        | 75      | 75  | 0.4=0.75 > 0.6   |       | Down     | U-shaped             |
| Cluster 9                  | No change | Up               | No change        | 9       | 9   | 0.4=0.75 < 0.6   | 9     | Up       | Bell-shaped          |
| Cluster 8                  | No change | No change        | Down             | 28      | 28  | 0.4=0.6 > 0.75   | 28    | Down     | 0.75xLD50 only       |
| Cluster 1                  | No change | Down             | Down, >0.6xLD50  | 216     | 220 | 0.4 > 0.75 > 0.6 | 220   | Down     | 0.4xLD50 - no effect |
| Cluster 4                  | No change | Down             | Down, >0.6xLD50  | 4       |     |                  |       |          |                      |

| D. 24 Hours Post-treatment |           |                  |                  |         |     |                  |       |          |                       |
|----------------------------|-----------|------------------|------------------|---------|-----|------------------|-------|----------|-----------------------|
| Cluster #                  | 0.4xLD50  | 0.6xLD50         | 0.75xLD50        | # Genes |     | Dose Response    | Total | Trend    | Pattern               |
| Cluster 6                  | Up        | Same as 0.4xLD50 | Up more          | 35      | 35  | 0.4=0.6 < 0.75   | 35    | Up       | Highest: 0.75xLD50    |
| Cluster 5                  | No change | No change        | Up               | 12      | 67  | 0.4=0.6 < 0.75   | 67    | Up       | 0.75xLD50 only        |
| Cluster 3                  | No change | No change        | Up               | 28      |     |                  |       | Up       |                       |
| Cluster 8                  | No change | No change        | Up               | 27      |     |                  |       | Up       |                       |
| Cluster 2                  | Down      | Same as 0.4xLD50 | Up               | 25      | 25  | 0.4=0.6 < 0.75   | 25    | Variable | Down then up          |
| Cluster 1                  | Down      | Same as 0.4xLD50 | No change        | 231     | 231 | 0.4=0.6 < 0.75   | 231   | Down     | 0.75xLD50 – no effect |
| Cluster 9                  | Up        | Same as 0.4xLD50 | Same as 0.4xLD50 | 256     | 256 | 0.4 = 0.6 = 0.75 | 256   | Up       | Dose independent      |
| Cluster 7                  | No change | Down             | Up               | 2       | 2   | 0.6 < 0.4 < 0.75 | 2     | Variable | Down then up          |
| Cluster 4                  | No change | Down             | No change        | 4       | 4   | 0.4=0.75 > 0.6   | 4     | Down     | U-shaped              |

| E. 2 Days Post-treatment |          |                  |                  |         |     |                  |       |       |                  |
|--------------------------|----------|------------------|------------------|---------|-----|------------------|-------|-------|------------------|
| Cluster #                | 0.4xLD50 | 0.6xLD50         | 0.75xLD50        | # Genes |     | Dose Response    | Total | Trend | Pattern          |
| Cluster 8                | Up       | Up more          | Same as 0.4xLD50 | 45      | 45  | 0.4=0.75 < 0.6   | 45    | Up    | Bell-shaped      |
| Cluster 9                | Up       | Same as 0.4xLD50 | Same as 0.4xLD50 | 258     | 258 | 0.4 = 0.6 = 0.75 | 258   | Up    | Dose independent |

|           |           |                  |                  |     |     |                    |     |          |                            |
|-----------|-----------|------------------|------------------|-----|-----|--------------------|-----|----------|----------------------------|
| Cluster 7 | Up (x2)   | Same as 0.4xLD50 | Down             | 7   | 7   | $0.4=0.75 > 0.6$   | 7   | Variable | Up then down               |
| Cluster 5 | Up        | No change        | Same as 0.4xLD50 | 3   | 167 | $0.4=0.75 > 0.6$   | 167 | Up       | U-shaped                   |
| Cluster 6 | Up        | No change        | Same as 0.4xLD50 | 164 |     |                    |     |          |                            |
| Cluster 4 | Up        | No change        | Down             | 1   | 1   | $0.4 > 0.75 > 0.6$ | 1   | Variable | Up then progressively down |
| Cluster 2 | No change | Down             | Up               | 18  | 91  | $0.6 < 0.4 < 0.75$ | 91  | Variable | Down then up               |
| Cluster 3 | No change | Down             | Up               | 73  |     |                    |     |          |                            |
| Cluster 1 | Down      | Down more        | Down more        | 275 | 275 | $0.4 > 0.6 > 0.75$ | 275 | Down     | Progressively down         |

| F. 5 Days Post-treatment |          |                  |                  |         |     |                    |       |          |                    |
|--------------------------|----------|------------------|------------------|---------|-----|--------------------|-------|----------|--------------------|
| Cluster #                | 0.4xLD50 | 0.6xLD50         | 0.75xLD50        | # Genes |     | Dose Response      | Total | Trend    | Expression Pattern |
| Cluster 1                | Up       | Up more          | Up more          | 137     | 229 | $0.4 < 0.6 < 0.75$ | 229   | Up       | Progressively up   |
| Cluster 2                | Up       | Up more          | Up more          | 92      |     |                    |       |          |                    |
| Cluster 3                | Up       | Same as 0.4xLD50 | Up more          | 80      | 80  | $0.4=0.6 < 0.75$   | 80    | Up       | Highest: 0.75xLD50 |
| Cluster 4                | Up       | Same as 0.4xLD50 | Same as 0.4xLD50 | 22      | 266 | $0.4 = 0.6 = 0.75$ | 266   | Up       | Dose independent   |
| Cluster 5                | Up       | Same as 0.4xLD50 | Same as 0.4xLD50 | 24      |     |                    |       |          |                    |
| Cluster 7                | Up       | Same as 0.4xLD50 | Same as 0.4xLD50 | 220     |     |                    |       |          |                    |
| Cluster 9                | Up       | Up, <0.4xLD50    | Same as 0.4xLD50 | 100     | 100 | $0.4=0.75 > 0.6$   | 100   | Up       | U-shaped           |
| Cluster 8                | Up       | Up, <0.4xLD50    | Same as 0.6xLD50 | 99      | 99  | $0.4 > 0.6=0.75$   | 99    | Up       | Highest: 0.4xLD40  |
| Cluster 6                | Up       | Down             | No change        | 109     | 109 | $0.4 > 0.75 > 0.6$ | 109   | Variable | Up then down       |

| G. 10 Days Post-treatment |           |                  |                         |         |     |                    |       |       |                   |
|---------------------------|-----------|------------------|-------------------------|---------|-----|--------------------|-------|-------|-------------------|
| Cluster #                 | 0.4xLD50  | 0.6xLD50         | 0.75xLD50               | # Genes |     | Dose Response      | Total | Trend | Pattern           |
| Cluster 9                 | No change | No change        | Down                    | 28      | 28  | $0.4=0.6 > 0.75$   | 186   | Down  | 0.75xLD50 only    |
| Cluster 7                 | Down      | Same as 0.4xLD50 | Down more               | 158     | 158 | $0.4=0.6 > 0.75$   |       | Down  | Lowest: 0.75xLD50 |
| Cluster 6                 | No change | Up               | No change               | 89      | 89  | $0.4=0.75 < 0.6$   | 89    | Up    | Bell-shaped       |
| Cluster 1                 | Down      | Down, >0.4xLD50  | Same as 0.4xLD50        | 106     | 106 | $0.4=0.75 < 0.6$   | 106   | Down  | Bell-shaped       |
| Cluster 2                 | Down      | No change        | Same as 0.4xLD50        | 43      | 65  | $0.4=0.75 < 0.6$   | 65    | Down  | Bell-shaped       |
| Cluster 3                 | Down      | No change        | Same as 0.4xLD50        | 15      |     |                    |       |       |                   |
| Cluster 5                 | Down      | No change        | Down more than 0.4xLD50 | 7       |     | $0.6 > 0.4 > 0.75$ |       | Down  |                   |
| Cluster 8                 | Down      | Same as 0.4xLD50 | Down more               | 71      | 71  | $0.4=0.6 > 0.75$   | 71    | Down  | Lowest: 0.75xLD50 |
| Cluster 4                 | Down      | Down, >0.4xLD50  | Down, >0.4xLD50         | 13      | 13  | $0.6 > 0.4 > 0.75$ | 13    | Down  | Bell-shaped       |

| H. 25 Days Post-treatment |          |          |           |         |     |                    |       |       |                  |
|---------------------------|----------|----------|-----------|---------|-----|--------------------|-------|-------|------------------|
| Cluster #                 | 0.4xLD50 | 0.6xLD50 | 0.75xLD50 | # Genes |     | Dose Response      | Total | Trend | Pattern          |
| Cluster 3                 | Up       | Up more  | Up more   | 132     | 132 | $0.4 < 0.6 < 0.75$ | 388   | Up    | Progressively up |

|           |           |                  |                  |     |     |                    |     |          |                            |
|-----------|-----------|------------------|------------------|-----|-----|--------------------|-----|----------|----------------------------|
| Cluster 6 | Down      | Up               | Up more          | 256 | 256 | $0.4 < 0.6 < 0.75$ |     | Variable | Down then progressively up |
| Cluster 2 | Up        | Up more          | Same as 0.6xLD50 | 208 | 888 | $0.4 < 0.6 = 0.75$ | 888 | Up       | Highest: 0.75xLD50         |
| Cluster 4 | Up        | Up more          | Same as 0.6xLD50 | 47  |     |                    |     |          |                            |
| Cluster 5 | Up        | Up more          | Same as 0.6xLD50 | 64  |     |                    |     |          |                            |
| Cluster 7 | Up        | Up more          | Same as 0.6xLD50 | 407 |     |                    |     |          |                            |
| Cluster 8 | Up        | Up more          | Same as 0.6xLD50 | 162 |     |                    |     |          |                            |
| Cluster 9 | No change | Up               | Same as 0.6xLD50 | 196 | 196 | $0.4 < 0.6 = 0.75$ | 196 | Up       | 0.4xLD50 – no effect       |
| Cluster 1 | Up        | Same as 0.4xLD50 | Same as 0.4xLD50 | 290 | 290 | $0.4 = 0.6 = 0.75$ | 290 | Up       | Dose independent           |

Despite the seemingly complex patterns of the clustering results, the dose response can generally be grouped in three categories:

1. Dose-dependent genes: These genes showed progressively up- or down-regulation along the dose range. In some cases, treatments with lower doses did not result in gene expression changes. This pattern of gene expression could be related to defense/repair response. Alternatively, they could also be related to toxicity.
2. Dose independent genes: These genes showed up- or down-regulation at the lowest dose. Treatments with higher doses did not result in larger changes in expression level. This pattern of gene expression is likely related to toxic response. However, their roles in defense/repair could not be ruled out without further verification.
3. Genes with altered response: These genes showed a response pattern with transitional changes. For instance, they were up-regulated at the lowest dose. However as the dose increases, they became down-regulated. An inverse pattern of such response was also observed. These genes are probably involved in the defense/repair response at the low dose and treatment-induced toxicity at the high dose.

Table 5 summarized the percentage of each category of the dose response at all eight time points. Dose dependent genes represent the majority (48-74%) of differentially expressed genes at three time points, 2 hours, 12 hours and 25 days post-treatment, while the genes showing altered response/transitional changes dominated the gene expression changes at the 6-hour time point. Interestingly, the differentially expressed genes almost evenly distribute across the three categories at two time points, 2 days and 5 days post-treatment. At two time points, the differentially expressed genes almost evenly distributed across two of the three categories, dose-independent and altered response categories at 24 hours, and dose-dependent and altered response categories at 10 days post-treatment.

**Table 5: Distribution of Differentially Expressed Genes across Dose-Dependent, Dose-Independent and Altered Response Categories**

| Time Points | Dose Response (% differentially Expressed Genes) |                  |          |
|-------------|--------------------------------------------------|------------------|----------|
|             | Dose-Dependent                                   | Dose-Independent | Variable |
| 2 Hours     | 48%                                              | 27%              | 25%      |
| 6 Hours     | 7%                                               | 0%               | 93%      |
| 12 Hours    | 74%                                              | 0%               | 26%      |
| 24 Hours    | 16%                                              | 41%              | 42%      |
| 2 Days      | 33%                                              | 31%              | 37%      |
| 5 Days      | 35%                                              | 30%              | 35%      |
| 10 Days     | 51%                                              | 0%               | 49%      |
| 25 Days     | 69%                                              | 16%              | 15%      |

### 3.3.2 Temporal Response of Hippocampal Gene Expression Following Sarin Treatment

Detailed examination of the lists of differentially expressed genes at the early and late time points allowed the identification of early-, delayed- and late-response genes, as well as the genes that showed persistent expression changes. Selected genes of interest are listed in the Tables 9 – 12.

**Table 6: Selected Early-Response Genes Following Sarin Treatment.**

| Gene Symbol* | Time Point (Hr) | Expression Level (Control)** | Post-Treatment Fold Change*** |          |          |           |
|--------------|-----------------|------------------------------|-------------------------------|----------|----------|-----------|
|              |                 |                              | Control                       | 0.4xLD50 | 0.6xLD50 | 0.75xLD50 |
| Ddit4        | 2               | 384.68                       | 1.00                          | 1.10     | 1.25     | 1.48      |
|              | 24              |                              | 1.00                          | 1.00     | -1.04    | -1.20     |
| Dusp1        | 2               | 547.52                       | 1.00                          | -1.07    | 1.03     | 2.15      |
|              | 48              |                              | 1.00                          | -1.01    | -1.11    | -1.39     |
| Npas4        | 2               | 261.65                       | 1.00                          | 1.25     | 1.16     | 4.26      |
|              | 6               |                              | 1.00                          | 1.70     | 1.93     | 2.43      |
|              | 12              |                              | 1.00                          | 1.54     | 1.51     | 1.88      |
|              | 120             |                              | 1.00                          | -1.16    | -1.61    | -1.98     |
| Nptx2        | 6               | 250.11                       | 1.00                          | -1.04    | 1.06     | 1.34      |
|              | 12              |                              | 1.00                          | -1.15    | 1.09     | 1.24      |
|              | 24              |                              | 1.00                          | 1.07     | 1.11     | 1.91      |
|              | 48              |                              | 1.00                          | 1.07     | 1.07     | 1.35      |
| Prps2        | 6               | 920.06                       | 1.00                          | -1.19    | -1.09    | -1.38     |
|              | 48              |                              | 1.00                          | 1.01     | -1.17    | -1.29     |
| Sept11       | 2               | 227.14                       | 1.00                          | -1.56    | -1.27    | -1.47     |
|              | 12              |                              | 1.00                          | -1.46    | -1.42    | -1.48     |
| Slc22a8      | 6               | 577.19                       | 1.00                          | 1.03     | 1.06     | -1.37     |
|              | 24              |                              | 1.00                          | -1.33    | -1.22    | -1.22     |
|              | 48              |                              | 1.00                          | -1.07    | -1.09    | -1.32     |

\*Genes showed significant expression changes within 6 hours after sarin treatment.

\*\*Average value of the relative expression levels of controls at the corresponding time points.

\*\*\*Negative fold change indicates down-regulation.

A brief description of the presently known functions of these early-response genes is shown below:

- a. **Ddit4 (DNA damage-inducible transcript 4 protein):** Ddit4 is downstream of AKT1. It inhibits cell growth by regulating the TSC1-TSC2 complex in the TOR signaling pathway. It can promote neuronal cell death. It is up-regulated in substantia nigra neurons from Parkinson disease patients. Ddit4 can be induced by DNA alkylation, ionizing radiation, amyloid beta-peptide and hypoxia.
- b. **Dusp1 (Dual specificity phosphatase 1):** Dusp1 plays an important role in the cellular response to environmental stress. It negatively regulates cell proliferation. Dusp1 inactivates mitogen-activated protein (MAP) kinase by concomitant dephosphorylation of both its phosphothreonine and phosphotyrosine residues. Dusp1 can be induced by oxidative stress, heat shock and growth factors.
- c. **Npas4 (Neuronal PAS domain protein 4):** It functions as a transcriptional activator in the presence of ARNT (aryl hydrocarbon receptor nuclear translocator). Npas4 activates the expression of the drebrin gene, which encodes for a cytoplasmic actin-binding protein that has a role in the process of neuronal growth, memory formation and Alzheimer's disease.
- d. **Nptx2 (Neuronal pentraxin II):** Nptx2 is a synaptic protein that is related to C-reactive protein. It is involved in excitatory synapse formation. It also has a role in the clustering of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors at established synapses, resulting in non-apoptotic cell death of dopaminergic nerve cells. Up-regulation of Nptx2 in Parkinson's disease (PD) tissues suggests that the protein may be involved in the pathology of PD.
- e. **Prps2 (phosphoribosyl pyrophosphate synthetase 2):** Prps2 encodes a phosphoribosyl pyrophosphate synthetase that plays a central role in the synthesis of purines and pyrimidines.
- f. **Sept11 (Septin 11):** Sept11 belongs to the septin family of filament-forming cytoskeletal GTPases that are involved in cytokinesis and vesicle trafficking. Sept11 may play a role in the neuronal cytoarchitecture, dendritic arborization and dendritic spines, and synaptic connectivity in GABAergic neurons.
- g. **Slc22a8 (Solute carrier family 22 (organic anion transporter), member 8):** Slc22a8 is involved in the sodium-independent transport and excretion of organic anions, some of which are potentially toxic. It has an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney.

**Table 7: Selected Delayed-Response Genes Following Sarin Treatment.**

| Gene Symbol* | Time Point (Hr) | Expression Level (Control)** | Post-Treatment Fold Change*** |          |          |           |
|--------------|-----------------|------------------------------|-------------------------------|----------|----------|-----------|
|              |                 |                              | Control                       | 0.4xLD50 | 0.6xLD50 | 0.75xLD50 |
| Acvr1c       | 12              | 265.99                       | 1.00                          | 1.01     | -1.19    | 1.07      |
|              | 24              |                              | 1.00                          | -1.08    | -1.45    | 1.30      |
|              | 48              |                              | 1.00                          | 1.10     | 1.02     | 1.52      |
|              | 240             |                              | 1.00                          | 1.01     | 1.43     | 1.37      |
| Ccnt1        | 12              | 889.74                       | 1.00                          | -1.17    | -1.48    | -1.45     |
|              | 240             |                              | 1.00                          | -1.12    | -1.23    | -1.30     |
| Hectd2       | 12              | 141.62                       | 1.00                          | 1.06     | 1.05     | 1.39      |
|              | 24              |                              | 1.00                          | 1.15     | 1.08     | 1.30      |
|              | 48              |                              | 1.00                          | 1.09     | 1.11     | 1.38      |
|              | 600             |                              | 1.00                          | 1.01     | 1.18     | 1.21      |
| Igfbp5       | 12              | 1057.11                      | 1.00                          | -1.00    | -1.23    | -1.28     |
|              | 24              |                              | 1.00                          | -1.29    | -1.15    | -1.33     |
|              | 48              |                              | 1.00                          | -1.07    | -1.14    | -1.42     |
| Nat13        | 12              | 497.75                       | 1.00                          | 1.27     | 1.36     | 1.41      |
|              | 48              |                              | 1.00                          | 1.04     | -1.04    | 1.45      |
| Nd6          | 12              | 686.11                       | 1.00                          | -1.27    | -1.25    | -1.49     |
|              | 120             |                              | 1.00                          | 1.49     | 1.47     | 1.57      |
|              | 240             |                              | 1.00                          | -1.14    | -1.29    | 1.99      |
| Nrn1         | 24              | 1492.70                      | 1.00                          | 1.01     | 1.25     | 1.39      |
|              | 48              |                              | 1.00                          | 1.08     | 1.17     | 1.36      |
| Ptgs2        | 24              | 397.31                       | 1.00                          | 1.15     | 1.24     | 1.81      |
|              | 48              |                              | 1.00                          | 1.05     | -1.11    | 1.41      |
|              | 120             |                              | 1.00                          | -1.05    | -1.21    | 1.09      |
| Scube1       | 24              | 302.68                       | 1.00                          | 1.07     | 1.02     | 1.46      |
|              | 48              |                              | 1.00                          | 1.01     | -1.02    | 1.35      |

\*Genes showed significant expression changes at or after 12 hours following sarin treatment.

\*\*Average value of the relative expression levels of controls at the corresponding time points.

\*\*\*Negative fold change indicates down-regulation.

A brief description of the presently known functions of these delayed-response genes is shown below:

- Acvr1c (Activin A receptor, type IC):** Acvr1c is a type I receptor for the TGF $\beta$  family of signaling molecules. Acvr1c forms a receptor complex upon ligand binding. Acvr1c has serine/threonine protein kinase activity. Acvr1c plays a role in cell differentiation, growth arrest and apoptosis.
- Ccnt1 (Cyclin T1):** Ccnt1 belongs to the highly conserved cyclin family. It tightly associates with CDK9 kinase, forming a complex called positive transcription elongation factor B (P-TEFb), which can facilitate the transition from abortive to productive elongation by phosphorylating the carboxyl-terminal domain of the large subunit of RNA polymerase II
- Hectd2 (HECT domain containing 2):** Hectd2 functions as an E3 ubiquitin-protein ligase that accepts ubiquitin from an E2 ubiquitin-conjugating enzyme and directly transfers the ubiquitin to targeted substrates.

- d. **Igfbp5 (Insulin-like growth factor binding protein 5):** Igfbp5 prolongs the half-life of the IGFs and can either inhibit or stimulate the growth promoting effects of IGFs on cell culture. It can also alter the interaction of IGFs with their cell surface receptors.
- e. **Nat13 (N-acetyltransferase 13):** Nat13 catalyzes the transfer of acetyl groups from acetyl-CoA to arylamines. This enzyme has broad specificity for aromatic amines, particularly serotonin.
- f. **Nd6 (NADH-ubiquinone oxidoreductase chain 6):** Nd6 is a core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), which functions in the transfer of electrons from NADH to the respiratory chain. Defects in MT-ND6 are a cause of Leber hereditary optic neuropathy (LHON), a maternally inherited disease resulting in optic nerve dysfunction and loss of central vision.
- g. **Nrn1 (neuritin 1):** Nrn1 promotes neurite outgrowth and arborization of neuritic processes in primary hippocampal and cortical cells. It is expressed in postmitotic-differentiating neurons and neuronal structures associated with neural plasticity. The expression of this gene can be induced by neural activity and neurotrophins.
- h. **Ptgs2 (Prostaglandin-endoperoxide synthase 2):** Ptgs2 is the key enzyme in prostaglandin biosynthesis. It also functions as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity. Expression Ptgs2 can be induced by cytokines and mitogens, which is responsible for the prostanoid biosynthesis involved in inflammation and mitogenesis, respectively.
- i. **Scube1 (Signal peptide, CUB domain, EGF-like 1):** Scube1 functions as an adhesive molecule. It is expressed in platelets and endothelial cells and its matrix bound and soluble fragments may play a critical role in vascular biology. Scube1 is down-regulated by inflammatory cytokines.

**Table 8: Selected Late-Response Genes Following Sarin Treatment.**

| Gene Symbol* | Time Point (Hr) | Expression Level (Control)** | Post-Treatment Fold Change*** |          |          |           |
|--------------|-----------------|------------------------------|-------------------------------|----------|----------|-----------|
|              |                 |                              | Control                       | 0.4xLD50 | 0.6xLD50 | 0.75xLD50 |
| Klk8         | 48              | 285.41                       | 1.00                          | -1.05    | -1.19    | 1.34      |
|              | 120             |                              | 1.00                          | 1.31     | 1.20     | 1.56      |
| Nr4a2        | 120             | 639.36                       | 1.00                          | 1.33     | 1.57     | 1.51      |
|              | 600             |                              | 1.00                          | 1.64     | 1.73     | 1.87      |

\*Genes that first showed significant expression changes at or after 48 hours following sarin treatment.

\*\*Average value of the relative expression levels of controls at the corresponding time points.

\*\*\*Negative fold change indicates down-regulation.

A brief description of the presently known functions of these late-response genes is shown below:

- a. **Klk8 (Kallikrein-related peptidase 8):** Klk8 is a serine protease that is capable of degrading a number of proteins such as fibrinogen, kininogen, fibronectin and collagen type IV. It cleaves L1CAM (L1 cell adhesion molecule) in response to increased neural activity. Klk8 induces neurite outgrowth and fasciculation of cultured hippocampal neurons. It plays a role in the formation and maturation of orphan and small synaptic boutons in the Schaffer-collateral pathway and regulates Schaffer-collateral long-term potentiation in the

hippocampus required for memory acquisition and synaptic plasticity. It also has a role in the secondary phase of pathogenesis following spinal cord injury. Klk8 is increased >10-fold in the hippocampus from patients with Alzheimer disease compared to controls.

- b. **Nr4a2 (Nuclear receptor subfamily 4, group A, member 2):** Nr4a2 is a member of the steroid-thyroid hormone-retinoid receptor superfamily. It functions as a general coactivator of gene transcription. Mutations in this gene have been associated with disorders related to dopaminergic dysfunction, including Parkinson disease, schizophrenia, and manic depression. Nr4a2 is rapidly and transiently expressed after cell activation, during the G0-G1 transition of the cell cycle. However, expression of Nr4a2 is not mandatorily associated with cell cycle.

**Table 9: Selected Persistent Genes Following Sarin Treatment.**

| Gene Symbol* | Time Point (Hr) | Expression Level (Control)** | Fold Change (Post-treatment)*** |          |          |           |
|--------------|-----------------|------------------------------|---------------------------------|----------|----------|-----------|
|              |                 |                              | Control                         | 0.4xLD50 | 0.6xLD50 | 0.75xLD50 |
| Dusp5        | 6               | 279.29                       | 1.00                            | 1.03     | 1.39     | 1.06      |
|              | 12              |                              | 1.00                            | 1.11     | 1.35     | 1.29      |
|              | 24              |                              | 1.00                            | 1.43     | 1.59     | 1.56      |
|              | 48              |                              | 1.00                            | 1.31     | 1.12     | 1.37      |
|              | 600             |                              | 1.00                            | 1.35     | 1.39     | 1.49      |
| Egr1         | 2               | 1103.11                      | 1.00                            | -1.05    | -1.13    | 1.44      |
|              | 12              |                              | 1.00                            | 1.27     | 1.38     | 1.72      |
|              | 24              |                              | 1.00                            | 1.05     | 1.00     | 1.55      |
|              | 120             |                              | 1.00                            | 1.33     | 1.43     | 1.51      |
|              | 600             |                              | 1.00                            | 1.28     | 1.21     | 1.11      |
| Egr2         | 6               | 145.72                       | 1.00                            | 1.14     | 1.58     | 1.30      |
|              | 12              |                              | 1.00                            | 1.13     | 1.18     | 1.44      |
|              | 24              |                              | 1.00                            | 1.14     | 1.27     | 1.36      |
|              | 600             |                              | 1.00                            | 1.48     | 1.43     | 1.16      |
| Egr3         | 6               | 548.96                       | 1.00                            | -1.12    | 1.13     | 1.24      |
|              | 12              |                              | 1.00                            | -1.02    | 1.03     | 1.36      |
|              | 24              |                              | 1.00                            | -1.05    | 1.00     | 1.56      |
|              | 120             |                              | 1.00                            | 1.11     | 1.16     | 1.30      |
| Epha6        | 6               | 180.83                       | 1.00                            | 1.50     | 1.24     | 1.48      |
|              | 12              |                              | 1.00                            | 1.12     | 1.22     | 1.56      |
|              | 48              |                              | 1.00                            | 1.06     | -1.08    | 1.36      |
|              | 600             |                              | 1.00                            | 1.10     | 1.49     | 1.43      |
| Inhba        | 6               | 210.72                       | 1.00                            | 1.07     | 1.23     | 1.54      |
|              | 12              |                              | 1.00                            | -1.19    | -1.39    | 1.68      |
|              | 24              |                              | 1.00                            | 1.11     | 1.12     | 1.70      |
|              | 48              |                              | 1.00                            | -1.07    | -1.12    | 1.55      |
|              | 120             |                              | 1.00                            | 1.05     | 1.23     | 1.31      |
|              | 600             |                              | 1.00                            | 1.12     | 1.14     | 1.34      |
| Per1         | 2               | 384.00                       | 1.00                            | -1.14    | 1.01     | 1.44      |
|              | 6               |                              | 1.00                            | -1.08    | 1.10     | 1.31      |
|              | 120             |                              | 1.00                            | 1.18     | 1.34     | 1.35      |
|              | 600             |                              | 1.00                            | 1.19     | 1.31     | 1.34      |

|          |     |        |      |       |       |       |
|----------|-----|--------|------|-------|-------|-------|
| Rasd1    | 2   | 220.04 | 1.00 | 1.02  | 1.11  | 1.56  |
|          | 12  |        | 1.00 | 1.16  | 1.34  | 1.58  |
|          | 24  |        | 1.00 | 1.25  | 1.29  | 1.71  |
|          | 120 |        | 1.00 | 1.30  | 1.28  | 1.53  |
| Tnfrsf25 | 2   | 129.25 | 1.00 | -1.12 | -1.26 | -1.41 |
|          | 48  |        | 1.00 | 1.23  | 1.27  | 1.36  |
|          | 600 |        | 1.00 | 1.25  | 1.40  | 1.39  |

\*Genes showed persistent expression changes (i.e., from early to late time points) after sarin treatment.

\*\*Average value of the relative expression levels of controls at the corresponding time points.

\*\*\*Negative fold change indicates down-regulation.

A brief description of the presently known functions of these persistently altered genes is shown below:

- a. **Dusp5 (Dual specificity phosphatase 5):** Dusp5 belongs to the protein-tyrosine phosphatase family, non-receptor class dual specificity subfamily. Dusp5 inactivates its target kinase by dephosphorylating both the phosphoserine/threonine and phosphotyrosine residues. It negatively regulates members of the mitogen-activated protein kinase superfamily, which are associated with cellular proliferation and differentiation. Dusp5 displays highest phosphatase activity toward ERK1 (Extracellular signal-regulated kinase 1). Dusp5 is localized in the nucleus and is highly expressed in brain.
- b. **Egr1 (Early growth response 1):** Egr1 functions as a transcriptional regulator. It activates the transcription of target genes that are required for mitogenesis and differentiation. Expression of Egr1 is induced by growth factors.
- c. **Egr2 (Early growth response 2):** Egr2 is a transcription factor. It binds to two specific DNA sites located in the promoter region of Hoxa4 (homeobox A4), a transcription factor that plays a role in the regulation of gene expression, morphogenesis, and differentiation. Egr2 interacts with HCFC1 (host cell factor C1), a protein involved in transcriptional regulation and cell cycle control during herpes simplex virus infection. Defects in Egr2 are associated with several diseases caused by hypomyelination neuropathy.
- d. **Egr3 (Early growth response 3):** Egr3 functions as a transcription factor. It is an immediate-early growth response gene which is induced by mitogenic stimulation. Egr3 participates in the transcriptional regulation of genes in controlling biological rhythm. It also has a role in a wide variety of processes such as negative regulation of apoptosis, endothelial cell growth and migration, and neuronal development.
- e. **Epha6 (Eph receptor A6):** Epha6, which belongs to the receptor tyrosine kinase family, is a receptor for members of the ephrin-A family. It binds GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Epha6 is involved in axon guidance.
- f. **Inhba (Inhibin beta-A):** Inhibins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, germ cell development and maturation, and nerve cell survival. Inhba is involved in cell cycle arrest and defense response.
- g. **Per1 (Period homolog 1 (Drosophila)):** Per1 is a component of the circadian clock mechanism, which is essential for generating circadian rhythms. It functions as a negative

element in the circadian transcriptional loop. Per1 influences clock function by interacting with other circadian regulatory proteins and transporting them to the nucleus. Phosphorylation of Per1 by CSNK1 (casein kinase 1) leads to its cytoplasmic retention and subsequent ubiquitination and degradation. Per1 is phosphorylated upon DNA damage, probably by ATM (ataxia telangiectasia mutated) or ATR (ataxia telangiectasia and Rad3 related). Per1 negatively regulates transactivation induced by Clock (circadian locomotor output cycles kaput) / Npas2 – ARNTL (aryl hydrocarbon receptor nuclear translocator-like)/ARNTL2 (aryl hydrocarbon receptor nuclear translocator-like 2).

- h. **Rasd1 (RAS, dexamethasone-induced 1):** Rasd1 is a small GTPase. It negatively regulates the transcription regulation activity of the APBB1 (amyloid beta (A4) precursor protein-binding, family B, member 1) – APP (amyloid beta (A4) precursor protein) complex via its interaction with APBB1. Rasd1 also forms a ternary complex with Nos1ap (nitric oxide synthase 1 (neuronal) adaptor protein) and NOS1 (nitric oxide synthase 1, neuronal). Rasd1 may play a role in dexamethasone-induced alterations in cell morphology, growth and cell-extracellular matrix interactions.
- i. **Tnfrsf25 (Tumor necrosis factor receptor superfamily, member 25):** Tnfrsf25 is a member of the TNF-receptor superfamily. Tnfrsf25 functions as a receptor for Tnfsf12 (tumor necrosis factor (ligand) superfamily, member 12). Tnfrsf25 interacts strongly via the death domains with Tnfrsf1 (tumor necrosis factor receptor superfamily, member 1) and Tradd (Tnfrsf1a-associated via death domain) to activate at least two distinct signaling cascades, apoptosis and NFκB (nuclear factor of kappa light polypeptide gene enhancer in B-cells) signaling pathway. Tnfrsf25 also interacts with Bag4 (Bcl2-associated athanogene 4), a member of the Bag1 antiapoptotic protein family.

### 3.4 Sarin-Induced Hippocampal Pathway Perturbation

Pathway perturbation at each time point following sarin treatment was determined by search the biological annotation databases with the differentially expressed genes as input data.

Statistically significant enrichment of differentially expressed genes in specific pathways and was interpreted as differential pathway modulation. Specifically, up-regulated pathways were identified using the list of up-regulated genes as input data, whilst the down-regulated pathways were identified using the list of down-regulated genes as input data. In addition, the up- and down-regulated genes were combined and used as input data in the analysis to identify pathways that have significant enrichment of differentially expressed genes. The complete lists of sarin-induced pathway perturbation all eight time points are shown in Supplemental Table 5, A-H.

The results of pathways perturbation at all time points were merged into a single file. Pathways were then categorized according to their biological functions. The results of pathway perturbation in four major functional classes, gene/protein expression, signaling pathways, defense/repair/cell death and neuronal/behavioral/cognitive functions, are shown in Tables 10-18.

#### 3.4.1 Gene Expression Process

Differential modulation of pathways involved in the gene expression process (including gene transcription, mRNA processing, mRNA transport, translation, post-translation modifications and protein transport) are shown in Tables 10-12.

### 3.4.1.1 Transcriptional and Posttranscriptional Regulations

Sarin treatment induced up-regulation of genes involved in transcription at multiple time points, especially 6 hours, 1-5 days and 25 days post-treatment (see Table 10). The increased gene transcription at 5 and 25 days and could be the result of down-regulation of transcription repressors/co-repressors at the 2-day time point. In addition, changes in the chromatin structures, a result of increased histone methylation and acetylation, likely played a role in the modulation of gene transcription as well. Although mRNA processing and transport also showed up-regulation at multiple time points, they do not completely coincide with gene transcription. For instance, up-regulation of mRNA processing occurred as early as 2 hours after sarin treatment, while up-regulation of transcription was only observed at the 6-hour time point. However, up-regulation of mRNA processing at later time points generally follows up-regulation of gene involved in transcription.

**Table 10: Perturbation of Pathways Involved in Transcriptional and Posttranscriptional Regulations in Hippocampus Following Sarin Treatment.<sup>1, 2</sup>**

| Transcription regulation, mRNA/ncRNA processing and transport        | Time Point (Hr) |       |       |     |       |     |       |     |
|----------------------------------------------------------------------|-----------------|-------|-------|-----|-------|-----|-------|-----|
|                                                                      | 2               | 6     | 12    | 24  | 48    | 120 | 240   | 600 |
| transcription                                                        |                 | red   |       |     |       | red |       | red |
| transcription regulation                                             |                 | red   |       | red | red   | red |       | red |
| positive regulation of transcription                                 |                 |       | green | red |       |     |       | red |
| negative regulation of transcription                                 |                 |       |       | red | red   |     |       | red |
| regulation of transcription from RNA polymerase II promoter          |                 |       |       |     | black |     |       |     |
| positive regulation of transcription from RNA polymerase II promoter |                 |       |       | red | green |     |       |     |
| negative regulation of transcription from RNA polymerase II promoter |                 |       |       | red |       |     |       |     |
| transcription cofactor activity                                      |                 |       |       |     | green |     |       |     |
| transcription repressor activity                                     |                 |       |       |     | black |     |       |     |
| transcription corepressor activity                                   |                 |       | green |     | green |     |       |     |
| chromosome organization                                              |                 |       |       |     |       |     |       | red |
| chromatin                                                            |                 |       |       |     |       | red |       |     |
| chromatin modification                                               |                 |       | green |     |       | red |       | red |
| chromatin remodeling complex                                         |                 |       |       |     |       | red |       |     |
| chromatin regulator                                                  |                 |       |       |     |       | red |       | red |
| histone modification                                                 |                 |       | green |     |       |     |       |     |
| histone methylation                                                  |                 |       |       |     |       |     |       | red |
| histone acetylation                                                  |                 |       | green |     |       | red |       |     |
| histone acetyltransferase complex                                    |                 |       | green |     |       |     |       |     |
| mRNA processing                                                      | red             | red   | green |     |       |     | green | red |
| ncRNA processing                                                     |                 |       |       |     |       |     | green |     |
| RNA splicing                                                         | red             | black |       |     | red   |     | green | red |
| Spliceosome                                                          | red             | green |       |     | red   | red |       | red |
| regulation of mRNA stability                                         | red             |       |       |     |       |     |       |     |
| mRNA transport                                                       |                 | black | red   |     |       | red |       | red |

<sup>1</sup>Statistically significant enrichment of differentially expressed genes in specific pathways was interpreted as pathway perturbation.

<sup>2</sup>Color scheme: red – enrichment of up-regulated genes; red and green – enrichment of both up- and down-regulated genes; green – enrichment of down-regulated genes; black– enrichment of differentially expressed genes.

### 3.4.1.2 Translational and Posttranslational Regulations

Translation, especially translation initiation, was also up-regulation at several time points following sarin treatment (see Table 11). Although the ribosomal subunits/proteins were strongly up-regulated at the 5-day time point, sarin treatment induced down-regulation of these genes at 2 hours post-treatment. The genes involved in protein transport showed a similar pattern of up-regulation (i.e., up-regulation at three time points). However, they were down-regulated at other time points. Protein folding and protein complex assembly were minimally affected at early time points; they showed up-regulation at the last time point 25 days.

**Table 11: Perturbation of Pathways Involved in Translational and Posttranslational Regulations in Hippocampus Following Sarin Treatment.<sup>1, 2</sup>**

| Translation egulation, post-translational modifications, protein transport | Time Point (Hr) |   |    |    |    |     |     |     |
|----------------------------------------------------------------------------|-----------------|---|----|----|----|-----|-----|-----|
|                                                                            | 2               | 6 | 12 | 24 | 48 | 120 | 240 | 600 |
| translation                                                                |                 |   |    |    |    |     |     |     |
| regulation of translation                                                  |                 |   |    |    |    |     |     |     |
| negative regulation of translation                                         |                 |   |    |    |    |     |     |     |
| translational initiation                                                   |                 |   |    |    |    |     |     |     |
| regulation of translational initiation                                     |                 |   |    |    |    |     |     |     |
| regulation of eIF4e and p70 S6 Kinase                                      |                 |   |    |    |    |     |     |     |
| translation initiation factor activity                                     |                 |   |    |    |    |     |     |     |
| translation elongation factor activity                                     |                 |   |    |    |    |     |     |     |
| ribonucleoprotein complex                                                  |                 |   |    |    |    |     |     |     |
| ribosome                                                                   |                 |   |    |    |    |     |     |     |
| ribosomal protein                                                          |                 |   |    |    |    |     |     |     |
| ribosomal subunit                                                          |                 |   |    |    |    |     |     |     |
| large ribosomal subunit                                                    |                 |   |    |    |    |     |     |     |
| protein localization                                                       |                 |   |    |    |    |     |     |     |
| regulation of protein localization                                         |                 |   |    |    |    |     |     |     |
| establishment of protein localization                                      |                 |   |    |    |    |     |     |     |
| protein transport                                                          |                 |   |    |    |    |     |     |     |
| regulation of protein transport                                            |                 |   |    |    |    |     |     |     |
| protein localization in organelle                                          |                 |   |    |    |    |     |     |     |
| protein localization in nucleus                                            |                 |   |    |    |    |     |     |     |
| protein import                                                             |                 |   |    |    |    |     |     |     |
| protein import into nucleus                                                |                 |   |    |    |    |     |     |     |
| protein targeting                                                          |                 |   |    |    |    |     |     |     |
| protein folding                                                            |                 |   |    |    |    |     |     |     |
| molecular chaperone                                                        |                 |   |    |    |    |     |     |     |
| posttranslational modification                                             |                 |   |    |    |    |     |     |     |
| glycoprotein biosynthetic process                                          |                 |   |    |    |    |     |     |     |
| protein complex assembly                                                   |                 |   |    |    |    |     |     |     |
| regulation of protein complex assembly                                     |                 |   |    |    |    |     |     |     |
| positive regulation of protein complex assembly                            |                 |   |    |    |    |     |     |     |
| regulation of protein complex disassembly                                  |                 |   |    |    |    |     |     |     |
| negative regulation of protein complex disassembly                         |                 |   |    |    |    |     |     |     |

<sup>1</sup>Statistically significant enrichment of differentially expressed genes in specific pathways was interpreted as pathway perturbation.

<sup>2</sup>Color scheme: red – enrichment of up-regulated genes; red and green – enrichment of both up- and down-regulated genes; green – enrichment of down-regulated genes; black – enrichment of differentially expressed genes.

### 3.4.1.3 Endomembrane System, Protein Folding and Ubiquitin-Mediated Proteolysis

The results shown above suggested that sarin treatment strongly stimulated transcription and translation. It was quite unexpected that the endoplasmic reticulum (ER) and Golgi apparatus, the subcellular organelles essential for processing (e.g., folding, post-translational modifications and packaging) the newly synthesized proteins, was strongly down-regulated in almost all time points analyzed in this study (except the last time point). Consistent with the down-regulation of the endomembrane system, up-regulation of ER overload, unfolded protein stress and ER stress was observed at the 5-day time point, which preceded the massive down-regulation of gene expression that occurred at 10 days post-treatment (see Table 12). In addition, the ubiquitin-mediated proteolysis was strongly up-regulated at five time points. This is probably the consequences of the dysregulation of the endomembrane system and the resulting ER overload/stress.

**Table 12: Perturbation of Pathways Involved in Endomembrane System, Protein Folding and Ubiquitin-Mediated Proteolysis in Hippocampus Following Sarin Treatment.**<sup>1, 2</sup>

| Endomembrane system & ubiquitin-mediated proteolysis       | Time Point (Hr) |   |    |    |    |     |     |     |
|------------------------------------------------------------|-----------------|---|----|----|----|-----|-----|-----|
|                                                            | 2               | 6 | 12 | 24 | 48 | 120 | 240 | 600 |
| endomembrane system                                        |                 |   |    |    |    |     |     |     |
| nuclear envelope-endoplasmic reticulum network             |                 |   |    |    |    |     |     |     |
| endoplasmic reticulum                                      |                 |   |    |    |    |     |     |     |
| ER-Golgi transport                                         |                 |   |    |    |    |     |     |     |
| Golgi apparatus                                            |                 |   |    |    |    |     |     |     |
| trans-Golgi network                                        |                 |   |    |    |    |     |     |     |
| vesicle                                                    |                 |   |    |    |    |     |     |     |
| vesicle-mediated transport                                 |                 |   |    |    |    |     |     |     |
| Golgi vesicle transport                                    |                 |   |    |    |    |     |     |     |
| nucleocytoplasmic transport                                |                 |   |    |    |    |     |     |     |
| unfolded protein response                                  |                 |   |    |    |    |     |     |     |
| ER overload response                                       |                 |   |    |    |    |     |     |     |
| response to endoplasmic reticulum stress                   |                 |   |    |    |    |     |     |     |
| ER-nuclear signaling pathway                               |                 |   |    |    |    |     |     |     |
| cellular protein catabolic process                         |                 |   |    |    |    |     |     |     |
| proteolysis involved in cellular protein catabolic process |                 |   |    |    |    |     |     |     |
| ER-associated protein catabolic process                    |                 |   |    |    |    |     |     |     |
| ubiquitin-dependent protein catabolic process              |                 |   |    |    |    |     |     |     |
| proteasomal ubiquitin-dependent protein catabolic process  |                 |   |    |    |    |     |     |     |
| ubl conjugation                                            |                 |   |    |    |    |     |     |     |
| ubl conjugation pathway                                    |                 |   |    |    |    |     |     |     |
| regulation of protein ubiquitination                       |                 |   |    |    |    |     |     |     |
| ubiquitin mediated proteolysis                             |                 |   |    |    |    |     |     |     |
| proteasome / proteasome complex                            |                 |   |    |    |    |     |     |     |

<sup>1</sup>Statistically significant enrichment of differentially expressed genes in specific pathways was interpreted as pathway perturbation.

<sup>2</sup>Color scheme: red – enrichment of up-regulated genes; green – enrichment of down-regulated genes; black – enrichment of differentially expressed genes.

### 3.4.2 Signaling Pathways

The signaling pathways essential for neuronal activities, neurotrophin signaling and Wnt signaling, were up-regulated at multiple time points (see Table 13). Although the TGF-beta signaling pathway is not neural specific, it has broad functions in the regulation of cell proliferation, differentiation, adhesion, migration in many cell types, including neuronal cells. Up-regulation of this pathway is therefore not unexpected. The ErbB, VEGF, Gonadotropin-releasing hormone (GnRH) and mTOR signaling pathways also showed alteration/up-regulation following sarin treatment. Since the MAP kinase pathway is the common down-stream signaling pathway for most of these pathways, it is up-regulated in almost all time points.

**Table 13: Perturbation of Signaling Pathways in Hippocampus Following Sarin Treatment.**<sup>1, 2</sup>

| Signaling Pathways                                               | Time Point (Hr) |   |    |    |    |     |     |     |
|------------------------------------------------------------------|-----------------|---|----|----|----|-----|-----|-----|
|                                                                  | 2               | 6 | 12 | 24 | 48 | 120 | 240 | 600 |
| TGF-beta signaling pathway                                       |                 |   |    |    |    |     |     |     |
| Neurotrophin signaling pathway                                   |                 |   |    |    |    |     |     |     |
| Wnt signaling pathway                                            |                 |   |    |    |    |     |     |     |
| ErbB signaling pathway                                           |                 |   |    |    |    |     |     |     |
| VEGF signaling pathway                                           |                 |   |    |    |    |     |     |     |
| GnRH signaling pathway                                           |                 |   |    |    |    |     |     |     |
| mTOR signaling pathway                                           |                 |   |    |    |    |     |     |     |
| enzyme linked receptor protein signaling pathway                 |                 |   |    |    |    |     |     |     |
| transmembrane receptor protein tyrosine kinase signaling pathway |                 |   |    |    |    |     |     |     |
| small GTPase mediated signal transduction                        |                 |   |    |    |    |     |     |     |
| MAPK signaling pathway                                           |                 |   |    |    |    |     |     |     |
| negative regulation of MAP kinase activity                       |                 |   |    |    |    |     |     |     |
| Phosphatidylinositol signaling system                            |                 |   |    |    |    |     |     |     |

<sup>1</sup>Statistically significant enrichment of differentially expressed genes in specific pathways was interpreted as pathway perturbation.

<sup>2</sup>Color scheme: red – enrichment of up-regulated genes; red and green – enrichment of both up- and down-regulated genes; green – enrichment of down-regulated genes; black – enrichment of differentially expressed genes.

### 3.4.3 DNA Damage/Repair, Glutathione Metabolism, Apoptosis and Tissue Repair

Sarin induces lethality mostly by inhibition of AChE and cholinergic overstimulation. Its effect on damage of subcellular organelles and other constituents is not well understood. The results in Table 14 strongly suggested that sarin exposure likely resulted in DNA damage, as the pathways involved in DNA repair were up-regulated at 6 hours after sarin treatment. Several members of the glutathione S-transferase (GST) family were down-regulated at two time points, 12 hours and 10 days, after sarin treatment. One of the functions of GST is to catalyze the conjugation of reduced glutathione to toxins, including (but not limited to) free radicals and reactive oxygen species, thereby detoxifying these compounds. In addition, GSTs could also bind to toxins and function as transport proteins. Down-regulation of such an important cellular defense system will likely further exacerbate the toxicity of sarin treatment, especially its DNA-damaging effects. The consequences of these events are thus likely the induction of apoptosis (and up-regulation of apoptosis regulation), which occurred three times (each covered two time points), with two of them occurring immediately after the GSTs down-regulation. Interestingly, genes

involved in the negative regulation of apoptosis were up-regulated at two time points, with one occurring at the later phase of the second peak of apoptosis. To counter these adverse events and re-establish a homeostatic state, pathways for repairing sarin-induced injury were activated. These include angiogenesis and wound healing.

**Table 14: Perturbation of Pathways Involved in DNA Damage/Repair, Glutathione Metabolism, Apoptosis and Tissue Repair in Hippocampus Following Sarin Treatment.**<sup>1, 2</sup>

| DNA damage/repair, glutathione metabolism, stress, apoptosis & tissue repair<br>(including angiogenesis) | Time Point (Hr) |   |    |    |    |     |     |     |
|----------------------------------------------------------------------------------------------------------|-----------------|---|----|----|----|-----|-----|-----|
|                                                                                                          | 2               | 6 | 12 | 24 | 48 | 120 | 240 | 600 |
| DNA damage                                                                                               |                 |   |    |    |    |     |     |     |
| DNA repair                                                                                               |                 |   |    |    |    |     |     |     |
| response to DNA damage stimulus                                                                          |                 |   |    |    |    |     |     |     |
| cellular response to stress                                                                              |                 |   |    |    |    |     |     |     |
| glutathione metabolism                                                                                   |                 |   |    |    |    |     |     |     |
| glutathione S-transferase, N-terminal                                                                    |                 |   |    |    |    |     |     |     |
| glutathione S-transferase, C-terminal                                                                    |                 |   |    |    |    |     |     |     |
| glutathione S-transferase, C-terminal-like                                                               |                 |   |    |    |    |     |     |     |
| glutathione S-transferase/chloride channel, C-terminal                                                   |                 |   |    |    |    |     |     |     |
| glutathione S-transferase, Mu class                                                                      |                 |   |    |    |    |     |     |     |
| metabolism of xenobiotics by cytochrome P450                                                             |                 |   |    |    |    |     |     |     |
| apoptosis                                                                                                |                 |   |    |    |    |     |     |     |
| regulation of apoptosis                                                                                  |                 |   |    |    |    |     |     |     |
| positive regulation of apoptosis                                                                         |                 |   |    |    |    |     |     |     |
| activation of caspase activity by cytochrome c                                                           |                 |   |    |    |    |     |     |     |
| negative regulation of apoptosis                                                                         |                 |   |    |    |    |     |     |     |
| negative regulation of neuron apoptosis                                                                  |                 |   |    |    |    |     |     |     |
| wound healing                                                                                            |                 |   |    |    |    |     |     |     |
| vasculature development                                                                                  |                 |   |    |    |    |     |     |     |
| blood vessel morphogenesis                                                                               |                 |   |    |    |    |     |     |     |
| angiogenesis                                                                                             |                 |   |    |    |    |     |     |     |
| regulation of angiogenesis                                                                               |                 |   |    |    |    |     |     |     |

<sup>1</sup>Statistically significant enrichment of differentially expressed genes in specific pathways was interpreted as pathway perturbation.

<sup>2</sup>Color scheme: red – enrichment of up-regulated genes; green – enrichment of down-regulated genes; black – enrichment of differentially expressed genes.

### 3.4.4 Neuronal Growth, Neuron Projection, Synaptic Structure, Synaptic Plasticity and Behavioral/Cognitive Functions

The genes in this category are among the most up-regulated genes. Additionally, they showed up-regulated at multiple time points. For instance, genes involved in neurogenesis and regulation of neurogenesis were up-regulated from 12 hours to 5 days following sarin treatment. However, up-regulation of genes involved in neuron differentiation and morphogenesis mainly occurred as a single peak at 48 hours post-treatment (Table 15).

**Table 15: Perturbation of Pathways Involved in Neuronal Growth and Differentiation in Hippocampus Following Sarin Treatment.<sup>1, 2</sup>**

| Neuronal growth & differentiation                     | Time Point (Hr) |       |       |     |     |       |       |     |
|-------------------------------------------------------|-----------------|-------|-------|-----|-----|-------|-------|-----|
|                                                       | 2               | 6     | 12    | 24  | 48  | 120   | 240   | 600 |
| regulation of cell proliferation                      | red             |       |       | red | red | red   | black |     |
| positive regulation of cell proliferation             | red             |       |       | red | red |       |       |     |
| negative regulation of cell proliferation             | red             |       |       |     |     |       |       |     |
| anti-proliferative protein                            |                 |       |       |     |     | green |       |     |
| regulation of growth                                  |                 |       | green | red |     | red   |       |     |
| cell proliferation in forebrain                       |                 |       |       |     | red |       |       |     |
| neurogenesis                                          |                 | black | red   |     |     | red   |       |     |
| regulation of neurogenesis                            |                 |       | black | red | red |       |       |     |
| mitotic cell cycle                                    |                 | red   | green |     |     | red   |       | red |
| regulation of cell cycle                              |                 |       | black |     |     |       |       |     |
| cell cycle arrest                                     |                 |       | black |     |     |       |       |     |
| mitotic sister chromatid segregation                  |                 |       |       |     |     |       |       | red |
| positive regulation of cell differentiation           |                 |       | green |     |     |       |       |     |
| negative regulation of cell differentiation           | red             |       |       | red |     | green |       |     |
| neuron differentiation                                |                 |       | green | red | red |       |       | red |
| regulation of neuron differentiation                  |                 |       | red   |     | red |       |       |     |
| cell morphogenesis involved in differentiation        |                 |       |       |     | red |       |       |     |
| cell morphogenesis involved in neuron differentiation |                 | red   |       |     | red | red   |       | red |
| neuron development                                    |                 |       |       |     | red |       |       |     |
| neuron maturation                                     |                 |       |       |     | red |       |       |     |
| regulation of cell size                               |                 |       |       |     | red |       |       |     |
| positive regulation of cell size                      |                 |       |       |     | red |       |       |     |

<sup>1</sup>Statistically significant enrichment of differentially expressed genes in specific pathways was interpreted as pathway perturbation.

<sup>2</sup>Color scheme: red – enrichment of up-regulated genes; green – enrichment of down-regulated genes; black – enrichment of differentially expressed genes.

Coincident with (or immediately following) the activation of the neuronal differentiation pathways, up-regulation of pathways with essential roles in neuron projection morphogenesis, axon guidance, axon extension, axon ensheathment and myelination was observed (Table 16). Unlike the pathways involved in the axonal morphogenesis, pathways with essential roles in dendritic arborization and synaptic structure were broadly up-regulated at almost all time points after sarin treatment.

**Table 16: Perturbation of Pathways Involved in Neuron Projection, Axonal, Dendritic and Synaptic Structure in Hippocampus Following Sarin Treatment.<sup>1, 2</sup>**

| Neuron projection, synaptic structures,           | Time Point (Hr) |   |    |    |    |     |     |     |
|---------------------------------------------------|-----------------|---|----|----|----|-----|-----|-----|
|                                                   | 2               | 6 | 12 | 24 | 48 | 120 | 240 | 600 |
| neuron projection                                 |                 |   |    |    |    |     |     |     |
| neuron projection development                     |                 |   |    |    |    |     |     |     |
| regulation of cell morphogenesis                  |                 |   |    |    |    |     |     |     |
| cellular component morphogenesis                  |                 |   |    |    |    |     |     |     |
| neuron projection morphogenesis                   |                 |   |    |    |    |     |     |     |
| regulation of neuron projection development       |                 |   |    |    |    |     |     |     |
| axonogenesis                                      |                 |   |    |    |    |     |     |     |
| regulation of axonogenesis                        |                 |   |    |    |    |     |     |     |
| positive regulation of axonogenesis               |                 |   |    |    |    |     |     |     |
| axon guidance                                     |                 |   |    |    |    |     |     |     |
| regulation of axon extension                      |                 |   |    |    |    |     |     |     |
| positive regulation of axon extension             |                 |   |    |    |    |     |     |     |
| axon                                              |                 |   |    |    |    |     |     |     |
| axon ensheathment                                 |                 |   |    |    |    |     |     |     |
| myelination                                       |                 |   |    |    |    |     |     |     |
| dendrite                                          |                 |   |    |    |    |     |     |     |
| dendrite development                              |                 |   |    |    |    |     |     |     |
| regulation of dendrite development                |                 |   |    |    |    |     |     |     |
| dendritic shaft                                   |                 |   |    |    |    |     |     |     |
| dendritic spine                                   |                 |   |    |    |    |     |     |     |
| synapse                                           |                 |   |    |    |    |     |     |     |
| synapse part                                      |                 |   |    |    |    |     |     |     |
| synapse organization                              |                 |   |    |    |    |     |     |     |
| synaptogenesis                                    |                 |   |    |    |    |     |     |     |
| presynaptic membrane                              |                 |   |    |    |    |     |     |     |
| synaptosome                                       |                 |   |    |    |    |     |     |     |
| synaptic vesicle                                  |                 |   |    |    |    |     |     |     |
| postsynaptic membrane                             |                 |   |    |    |    |     |     |     |
| postsynaptic density                              |                 |   |    |    |    |     |     |     |
| ionotropic glutamate receptor, AMPA/kainate types |                 |   |    |    |    |     |     |     |

<sup>1</sup>Statistically significant enrichment of differentially expressed genes in specific pathways was interpreted as pathway perturbation.

<sup>2</sup>Color scheme: red – enrichment of up-regulated genes; green – enrichment of down-regulated genes; black – enrichment of differentially expressed genes.

As the pathways for neuronal projection, axonal morphogenesis, dendritic arborization and synaptic structure were strongly activated, synaptic transmission (including postsynaptic membrane potential) and synaptic plasticity (e.g. long-term potentiation) were also broadly up-regulated (Table 17).

**Table 17: Perturbation of Pathways Involved in Synaptic Transmission and Synaptic Plasticity in Hippocampus Following Sarin Treatment.<sup>1, 2</sup>**

| Synaptic transmission, membrane potential                | Time Point (Hr) |   |    |    |    |     |     |     |
|----------------------------------------------------------|-----------------|---|----|----|----|-----|-----|-----|
|                                                          | 2               | 6 | 12 | 24 | 48 | 120 | 240 | 600 |
| transmission of nerve impulse                            |                 |   |    |    |    |     |     |     |
| regulation of transmission of nerve impulse              |                 |   |    |    |    |     |     |     |
| positive regulation of transmission of nerve impulse     |                 |   |    |    |    |     |     |     |
| synaptic transmission                                    |                 |   |    |    |    |     |     |     |
| nerve-nerve synaptic transmission                        |                 |   |    |    |    |     |     |     |
| synaptic transmission, glutamatergic                     |                 |   |    |    |    |     |     |     |
| regulation of synaptic transmission                      |                 |   |    |    |    |     |     |     |
| positive regulation of synaptic transmission             |                 |   |    |    |    |     |     |     |
| regulation of membrane potential                         |                 |   |    |    |    |     |     |     |
| regulation of postsynaptic membrane potential            |                 |   |    |    |    |     |     |     |
| regulation of excitatory postsynaptic membrane potential |                 |   |    |    |    |     |     |     |
| regulation of action potential                           |                 |   |    |    |    |     |     |     |
| regulation of action potential in neuron                 |                 |   |    |    |    |     |     |     |
| regulation of synaptic plasticity                        |                 |   |    |    |    |     |     |     |
| regulation of neuronal synaptic plasticity               |                 |   |    |    |    |     |     |     |
| regulation of long-term neuronal synaptic plasticity     |                 |   |    |    |    |     |     |     |
| Long-term potentiation                                   |                 |   |    |    |    |     |     |     |
| Long-term depression                                     |                 |   |    |    |    |     |     |     |

<sup>1</sup>Statistically significant enrichment of differentially expressed genes in specific pathways was interpreted as pathway perturbation.

<sup>2</sup>Color scheme: red – enrichment of up-regulated genes; green – enrichment of down-regulated genes; black – enrichment of differentially expressed genes.

Similar to the pathways involved in synaptic transmission and synaptic plasticity, pathways related to behavioral and cognitive functions (e.g., learning and memory) were also up-regulated at multiple time points (see Table 18). This is expected; in fact these behavioral and cognitive functions are supported by neurological function such as synaptic transmission and synaptic plasticity. Interestingly, the pathways related to several neurodegenerative diseases were up-regulated at the 5-day time point, which precedes the massive gene depression in hippocampus that occurred at the 10-day time point.

**Table 18: Perturbation of Pathways Involved in Behavioral/Cognitive Functions and Neurodegenerative Diseases in Hippocampus Following Sarin Treatment.<sup>1, 2</sup>**

| Behavioral and cognitive functions & neurodegenerative diseases | Time Point (Hr) |   |    |    |    |     |     |     |
|-----------------------------------------------------------------|-----------------|---|----|----|----|-----|-----|-----|
|                                                                 | 2               | 6 | 12 | 24 | 48 | 120 | 240 | 600 |
| behavior                                                        |                 |   |    |    |    |     |     |     |
| locomotory behavior                                             |                 |   |    |    |    |     |     |     |
| visual behavior                                                 |                 |   |    |    |    |     |     |     |
| learning or memory                                              |                 |   |    |    |    |     |     |     |
| learning                                                        |                 |   |    |    |    |     |     |     |
| memory                                                          |                 |   |    |    |    |     |     |     |
| visual learning                                                 |                 |   |    |    |    |     |     |     |
| fear response                                                   |                 |   |    |    |    |     |     |     |
| sensory perception of pain                                      |                 |   |    |    |    |     |     |     |
| Alzheimer's disease                                             |                 |   |    |    |    |     |     |     |
| Huntington's disease                                            |                 |   |    |    |    |     |     |     |
| Parkinson's disease                                             |                 |   |    |    |    |     |     |     |
| Amyotrophic lateral sclerosis (ALS)                             |                 |   |    |    |    |     |     |     |

<sup>1</sup>Statistically significant enrichment of differentially expressed genes in specific pathways was interpreted as pathway perturbation.

<sup>2</sup>Color scheme: red – enrichment of up-regulated genes; black – enrichment of differentially expressed genes.

#### 4. DISCUSSION

Sublethal sarin exposure induced prolonged impairment of cognitive and neurobehavioral functions (Kassa et al, 2001a; Kassa et al, 2001b; Hulet et al, 2002; Kassa et al, 2004; Grauer et al, 2008). For instance, mice exposed to an asymptomatic dose of sarin display long-lasting deficiency in emotional learning (Lucot, personal communication). These observations suggested that traditional methods for assessing sarin toxicity lack the sensitivity to detect the changes associated with organ injury. Therefore, the goal of this study is to investigate the effects of sublethal sarin exposure on gene expression, based on the rationale that the gene expression changes could serve as sensitive indicators of sarin-induced injury. Additionally, pathway perturbation, resulted from gene expression changes, could provide novel insights into the molecular mechanism(s) of sarin-induced organ injury.

Three doses of sarin, 0.4x, 0.6x, and 0.75x LD50, were used in this study. The results in Figure 2 show that while the two lower doses are asymptomatic or mildly symptomatic (based on functional observations), the highest dose, 0.75x LD50, caused observable signs of sarin intoxication. Therefore, the dose range employed in this study provided a good coverage for sarin-induced injury.

Compared to functional observation assessment, analysis of AChE inhibition in both brain and blood appeared to be more sensitive in detecting sarin toxicity, as significant (although relatively small) decreases in AChE activities were observed in some animals treated with the lowest dose, 0.4x LD50. Consistent with this notion, most of the animals treated with sarin at 0.6x LD50 showed a significant inhibition of AChE in frontal lobe. Blood AChE seemed to be highly sensitive to sarin exposure, as the lowest dose (0.4x LD50) caused significant AChE inhibition

up to 12 hours post-treatment. However, the enzyme activity quickly recovered after this time points even in the animals treated with 0.6x and 0.65x LD50. Analysis of BuChE activity seemed to be rather insensitive in detecting sarin exposure, as most animals treated with the highest dose, 0.75xLD50, did not show statistically significant inhibition.

Although six brain regions and six peripheral organs have been collected from control and sarin-treated animals, funding received only allows the analysis of one brain region (or organ). Hippocampus is one of the most sensitive brain regions to sarin-induced injury. For instance, neural injury in the dentate gyrus is detectable very early after sarin treatment (Lucot, personal communication). Additionally, this brain region plays a critical role in cognitive functions, such as learning and memory. Decline in memory performance, including impairment of working and reference memory processes, has been reported to be the major long-lasting effects resulted from sublethal sarin exposure (Hatta et al., 1996; Yokoyama et al. 1998; Kassa et al, 2001a; Kassa et al, 2001b; Kassa et al, 2004). Because of these reasons, hippocampus was chosen as the first sample set for the investigation of sarin-induced differential gene expression and pathway perturbation.

Gene expression profiling revealed that sarin treatment resulted in differential expression of a large number of genes - from several hundred to approximately two thousand genes, dependent on the time after the treatment. The numbers of differentially expressed genes are significantly higher than expected. This is probably due to the fact that an exon array, which contains probe sets for >300,000 transcripts (including alternatively spliced products), was used in this study. Although a filter for eliminating low-quality probes was implemented during data analysis, expression profiles of ~129,000 transcripts nevertheless were obtained. Compared to the expression profiles of ~25,000 transcripts, this dataset is thus significantly richer than that obtained using microarray based on probe sets designed around the 3' end of the mRNAs. Additionally, the option of all pair-wise comparison was selected during data analysis. This option allowed the identification of not only the genes showing sarin-induced differential expression, but also the genes showing differential dose response.

SOM clustering analysis is a very powerful pattern recognition technique for identifying gene groups with unique dose response. Using this technique, the seemingly complex patterns of sarin-induced differential gene expression could be effectively separated into three categories, dose-dependent, dose independent and response with transitional changes. Based on the dose response pattern, the roles of these gene categories in the response to sarin toxicity can be estimated. For instance, dose-dependent genes are likely related to defense/repair, while dose independent genes are probably involved in toxic response. As such this scientific logic/conjecture is not definitive as the biological significance of these gene expression changes must be validated.

Detailed examination of the gene expression changes that occurred at early and late time points reveal an interesting pattern of temporal response of sarin-induced differential gene expression. At early time points, a significant number of genes encoding for transcription activator (e.g. Npas4), or signaling pathways regulators (e.g. Ddit4) with gene expression as downstream targets, were up-regulated. These changes likely set the stage of large scale differential gene expression at later time points.

The observation of Nptx2 up-regulation at early time points is of particular interest. Moran et al (2008) reported Nptx2 protein was increased in PD tissues and suggested that it may be involved in the pathology of this disease. A number of investigators have shown that OP exposure induced PD-like symptoms, which might be mechanistically related to alterations in the dopaminergic system (Karen et al, 200; Choudhary et al, 2002; Masoud et al, 2011; Torres-Altora et al, 2011). However, the result reported here that Nptx2 was up-regulated after sarin treatment provides an alternative mechanism for OP-induced PD-like symptoms.

At the later time points, the toxic effect of sarin emerged, as evidenced by the up-regulation of genes involved in neural inflammation and apoptosis (e.g. Ptgs2 and Acvr1c). Consistent with this observation, other investigators also reported that sarin (and soman) exposure that caused no overt clinical signs resulted in an inflammatory response, as indicated by the increases in brain mRNAs for interleukin (IL)-1 $\beta$ , tumor necrosis factor- $\alpha$ , and IL-6 (Svensson et al., 2001; Henderson et al, 2002). At these later time points, proteolysis was initiated to clear the damaged proteins (e.g. up-regulation of Hectd2).

Considering the large number of genes that showed differential expression at the 25-day time point, it is quite unexpected that the number of late response genes is relatively small. Close examination revealed that most of the genes that are differentially expressed at late time points also showed expression changes at early time points. In other words, these genes showed persistent expression changes from early to late time points. Interestingly, transcription regulators are quite common among these persistently altered genes (e.g. Egr1, Egr2 and Egr3). Receptors and signaling pathway regulators, with roles in neuronal morphology, cell cycle regulation, defense response and apoptosis, are also common.

Despite that these results provided interesting information on gene expression changes following sarin exposure, they provided limited insight into the mechanism of sarin-induced delay neurotoxicity as reported in the literature (Husain et al, 1993; Nishiwaki et al, 2001; Miyaki et al, 2005). To address this issue, analysis of pathway perturbation was thus conducted. Consistent with the result of temporal gene expression analysis, sarin treatment appears to activate gene transcription pathways at multiple time points, especially 6 hours, 1, 2, 5 and 25 days post-treatment. To facilitate gene transcription, coordinated changes in chromatin structures (resulted from histone methylation/acetylation), mRNA processing/transport were also observed. Increased gene transcription following sarin treatment is expected, as it is essential for almost all cellular responses, including defense, repair and toxic responses, to exogenous insults/stressors. As translation is also an essential process for almost all defense, repair and toxic responses to exogenous insults/stressors, it is also strongly up-regulated following sarin treatment. In addition, the pathways related to protein transport showed a similar pattern of activation. Taken together, these results suggested that after sarin treatment, cells strongly activated the genes expression process to counter the adverse effects of sarin toxicity.

However, successful defense against sarin toxicity and repair of sarin-induced injury require not only protein synthesis, but also proper processing (such as folding and post-translational modifications) of the newly synthesized proteins and transporting the processed proteins to the subcellular sites, in which they perform their functions. The endomembrane system (including

the ER and the Golgi apparatus) is critical for protein processing, packaging and transport. Down-regulation of the ER and the Golgi apparatus at multiple time points after sarin treatment strongly suggested the newly synthesized proteins were not processed or transported out of the ER/Golgi apparatus, resulting in the accumulation of unprocessed/unfolded proteins in ER and subsequently ER overload and ER stress. This creates a scenario that on one hand, the sarin-induced damage could not be repaired, and on the other hand, the injured cells are under additional stress due to accumulation of unfolded proteins in ER. The combined effects of persistent presence of unrepaired damage and ER stress will likely trigger and perhaps even accelerate cell death.

Although sarin lethality through inhibition of AChE and cholinergic overstimulation is well established, the mechanism of sarin cellular toxicity is not completely clear, nor the effect of sarin on DNA damage. Klein et al (1987) reported that no increase in unscheduled DNA synthesis was observed in sarin-treated hepatocytes. On the contrary, significant decreases in DNA repair synthesis were detected. Based on these results, these investigators concluded that sarin may either inhibit DNA repair or protect DNA from damage. However, a more recent study showed that repeated low-dose (0.2x and 0.4x LD50) sarin exposure resulted in a significant increase in DNA fragmentation in leukocytes (Dave et al, 2007). However, a systematic dose-dependent response was not observed in parietal cortex, although DNA fragmentation did occur in some cases. The results of pathway analysis reported here strongly suggested that sarin likely caused DNA damage, as pathways related to DNA repair were up-regulated at 6 hour post-treatment. Besides DNA damage, sarin treatment also activated other stress response, as well as apoptosis (which can be considered as the “ultimate, uncompromised” stress response), at several time points. It should be noted that up-regulation of genes involved in the apoptosis pathway does not necessarily means that the apoptotic process is in fact executed. However, activation of pathways involved in tissue repair, such as wound healing and vasculature development, suggested the occurrence of sarin-induced injury, regardless the mechanisms of cell death (e.g. necrosis, apoptosis or both). Given the activation of stress response after sarin treatment, it is quite expected that several members of the glutathione S-transferase (GST) family were down-regulated at two time points after sarin treatment. Down-regulation of the GST defense system will likely further exacerbate the adverse effects of sarin toxicity.

Signaling pathways serve as the communication network in the cells. For instance, activation of VEGF signaling pathway results in angiogenesis, a tissue repair pathway that was up-regulated as described above. Similarly, activation of the neurotrophin, Wnt, TGF-beta and ErbB signaling pathways, which can stimulate neuronal cells proliferation, differentiation and morphogenesis, is probably part of the repair process. Consistent with this premise, up-regulation of pathways related to neuronal growth/differentiation (e.g. neurogenesis, regulation of neurogenesis and neuronal differentiation), neuron projection development (e.g. neuron projection morphogenesis, axon guidance, axon ensheathment/myelination and dendritic arborization) and synapse organization (e.g. synaptogenesis, presynaptic membrane and postsynaptic density) was observed at multiple time points after sarin treatment. These structural changes could thus support the functional enhancement in synaptic transmission, synaptic plasticity (e.g. long-term potentiation and long-term depression) and cognitive functions (e.g., learning and memory). Interestingly, pathways related to several neurodegenerative diseases

were up-regulated at 5 days post-treatment, due to differential expression of genes involved in mitochondrial dysfunction. This result suggested that mitochondrion could also be an intracellular target of sarin. However, this has to be confirmed in future studies.

The results of pathway analysis at each time point provided a snapshot of the events following sarin treatment. Based on the sequence and the biological significance of these events, a model that aims to provide a mechanistic basis for sarin-induced hippocampal injury is proposed as outlined below.

1. Upon sarin exposure, cellular damage (e.g. DNA damage) occurred. As a result, the apoptotic pathway was activated. Proliferation pathway, as part of the repair process, was also activated. This response was supported by the processing of existing transcripts, rather than synthesis of new transcripts.
2. Cellular damage subsequently activated the DNA repair pathway and the clearance of the damaged proteins by proteolysis. Signaling pathways were activated to coordinate the cellular response. This includes the repair processes, which is supported by gene transcription, RNA processing/transport, translation, protein processing/transport. The newly transcribed genes are involved in proliferation, differentiation, neuronal projection, axonal, dendritic, and synaptic structures, neurological and cognition functions. However, down-regulation of ER and the Golgi apparatus occurred, resulting in dysfunction of the endomembrane system (such as dysregulation of the ER-Golgi transport and the trans-Golgi network). As the endomembrane system has a critical role in the processing of the newly synthesized proteins, damage to this subcellular organelle has significant consequences.
3. Signaling pathways that coordinate the repair process (including the gene/protein expression process, cell proliferation, differentiation, neuronal morphogenesis, and neurological and cognition functions) remained activated. However, the effects of sarin-induced cellular damage became more apparent. This includes not only dysfunction of the endomembrane system, but also the suppression of the GST defense system, which prevents the detoxification and removal of toxic compounds. Proteolysis for clearing the damaged proteins remained activated.
4. As sarin-induced injury persisted, signaling pathways that coordinate the repair process remained activated. However, apoptosis is activated in the cells that were unable to repair the damage. At the same time, pathways for tissue repair were also activated. Dysfunction of the endomembrane system became more significant, which prevented the newly synthesized proteins to be properly processed, correctly folded and transported to the target sites. As a result, the gene/protein expression that is to support the repair process remained highly activated. Persistent up-regulation of the gene/protein expression process and dysfunction of the endomembrane system resulted in the accumulation of unfolded proteins in the ER (i.e., ER overload), ER stress and subsequently cell death, which is associated with a broad spectrum of gene suppression at 10 days post-treatment.
5. However, this cycle of gene/protein expression – ER stress – cell death may repeat many times long after the exposure, as suggested by the similar patterns of gene expression and

pathway perturbation at 6 hours and 25 days. Such repeated cycle of neuronal cell death is likely the basis for sarin-induced delayed neurotoxicity and cognitive impairments as described in the literature (Husain et al, 1993; Nishiwaki et al, 2001; Miyaki et al, 2005).

## 5. CONCLUSION

In this study, differential gene expression in the hippocampal region was investigated in mice treated with sublethal doses of sarin using DNA microarray technology. Detailed interpretation of the microarray data using advanced bioinformatic techniques allows the identification of pathway modulation/perturbation in response of sarin-induced injury. Integration of these events, based on their biological significance and the temporal sequence of their occurrence, afforded a mechanistic model for sarin-induced delayed neurotoxicity. Testing/validation and overall accuracy of the developed model will require further studies and are the goals of future studies. Do note, all reference to changes in brain tissue is based upon mRNA data and major pathway effectors, and has not been fully referenced by protein content or protein activities data.

In addition to these accomplishments, it should also be emphasized that a number of brain regions and major peripheral organs from sarin-treated (and control) animals have been isolated and preserved. Analysis of gene expression changes and pathway perturbation using these specimens will provide a thorough understanding of sarin-induced differential gene expression, pathway perturbation and injury in these tissues. Integration of the results of this study and those that derived from future studies using the preserved tissues will reveal the molecular mechanism of sarin-induced injury at the organism level. This will significantly facilitate the efforts aiming to develop countermeasures against this chemical warfare agent.

## 6. REFERENCES

- Abou-Donia MB (1995) Involvement of cytoskeletal proteins in the mechanisms of organophosphorus ester-induced delayed neurotoxicity Clin Exp Pharmacol Physiol 22(5):358–369.
- Allon N, Rabinovitz I, Manistersky E, Weissman BA, Grauer E. (2005) Acute and long-lasting cardiac changes following a single whole-body exposure to sarin vapor in rats. Toxicol Sci 87:385-90.
- Anzueto A, deLemos RA, Seidenfeld J, Moore G, Hamil H, Johnson D, Jenkinson SG. (1990) Acute inhalation toxicity of soman and sarin in baboons. Fundam Appl Toxicol. 14:676-87.
- Bloch-Shilderman E, Levy A. (2007) Transient and reversible nephrotoxicity of sarin in rats. J Appl Toxicol 27:189-94.
- Choudhary S, Raheja G, Gupta V, Gill KD. (2002) Possible involvement of dopaminergic neurotransmitter system in dichlorvos induced delayed neurotoxicity. J Biochem Mol Biol Biophys 6:29-36.

Dave JR, Connors RA, Genovese RF, Whipple RA, Chen RW, DeFord SM, Moran AV, Tortella EC. (2007) DNA fragmentation in leukocytes following repeated low dose sarin exposure in guinea pigs. *Cell Mol Life Sci* 64:2823-8.

Davidson ME, Kerepesi LA, Soto A, Chan VT. (2008) D-Serine Exposure Resulted in Gene Expression Changes Implicated in Neurodegenerative Disorders and Neuronal Dysfunction in Male Fischer 344 Rats. *Arch Toxicol* 83:747-62.

Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol.* 7:88-95.

Fernando JC, Lim DK, Hoskins B, Ho IK (1985) Variability of neurotoxicity of and lack of tolerance to the anticholinesterases soman and sarin in the rat. *Res Commun Chem Pathol*

Genovese RF, Oubre JL, Jakubowski EM, Fleming PJ, Saxena A, Rockwood GA, Tipparaju P, Willmore CB. (2007b) Evaluation of cognitive and biochemical effects of low-level exposure to sarin in rhesus and African green monkeys. *Toxicology* 231:11-20.

Genovese RF, Mioduszewski RJ, Benton BJ, Pare MA, Cooksey JA. (2008) Behavioral evaluation of rats following low-level inhalation exposure to sarin. *Pharmacol Biochem Behav* 91:517-25.

Grauer E, Chapman S, Rabinovitz I, Raveh L, Weissman BA, Kadar T, Allon N. (2008) Single whole-body exposure to sarin vapor in rats: long-term neuronal and behavioral deficits. *Toxicol Appl Pharmacol* 227:265-74.

Hatta K, Miura Y, Asukai N, Hamabe Y. (1996) Amnesia from sarin poisoning. *Lancet* 347:1343.

Henderson RF, Barr EB, Blackwell WB, Clark CR, Conn CA, Kalra R, March TH, Sopori ML, Tesfaigzi Y, Ménache MG, Mash DC. (2002) Response of rats to low levels of sarin. *Toxicol Appl Pharmacol.* 184:67-76.

Holm, S. (1979). A simple sequentially rejective multiple test procedure. *Scand J Stat* 6: 65–70.

Huang W, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA. (2007) DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. *Nucleic Acids Res* 35(Web Server issue):W169-75.

Hulet SW, McDonough JH, Shih TM. (2002) The dose-response effects of repeated subacute sarin exposure on guinea pigs. *Pharmacol Biochem Behav* 72:835-45.

Husain K, Vijayaraghavan R, Pant SC, Raza SK, Pandey KS. (1993) Delayed neurotoxic effect of sarin in mice after repeated inhalation exposure. *J Appl Toxicol.* 13:143-5.

Kadar, T., S. Shapira, G. Cohen, R. Sahar, D. Alkalay and L. Raveh, (1995) Sarin-induced neuropathology in rats, *Hum Exp Toxicol* 14: 252–259.

Karen DJ, Li W, Harp PR, Gillette JS, Bloomquist JR. (2001) Striatal dopaminergic pathways as a target for the insecticides permethrin and chlorpyrifos. *Neurotoxicology* 22:811-7.

Kassa J, Koupilová M, Vachek J. (2001a) Long-term effects of low-level sarin inhalation exposure on the spatial memory of rats in a T-maze. *Acta Medica (Hradec Kralove)* 44:93-6.

Kassa J, Koupilová M, Vachek J. (2001b) The influence of low-level sarin inhalation exposure on spatial memory in rats. *Pharmacol Biochem Behav.* 70:175-9.

Kassa J, Pecka M, Tichý M, Bajgar J, Koupilová M, Herink J, Krocová Z. (2001c) Toxic effects of sarin in rats at three months following single or repeated low-level inhalation exposure. *Pharmacol Toxicol* 88:209-12.

Kassa J, Krejcová G, Vachek J. (2002) The impairment of spatial memory following low-level sarin inhalation exposure and antidotal treatment in rats. *Acta Medica (Hradec Kralove)* 45:149-53.

Kassa J, Krejcová G, Skopec F, Herink J, Bajgar J, Sevelová L, Tichý M, Pecka M. (2004) The influence of sarin on various physiological functions in rats following single or repeated low-level inhalation exposure. *Inhal Toxicol* 16:517-30.

Klein AK, Nasr ML, Goldman M. (1987) The effects of in vitro exposure to the neurotoxins sarin (GB) and soman (GD) on unscheduled DNA synthesis by rat hepatocytes. *Toxicol Lett* 38:239-49.

Landauer MR, Romano JA. (1984) Acute behavioral toxicity of the organophosphate sarin in rats. *Neurobehav Toxicol Teratol.* 6:239-43.

Masoud A, Kiran R, Sandhir R. (2011) Modulation of dopaminergic system and neurobehavioral functions in delayed neuropathy induced by organophosphates. *Toxicol Mech Methods* 21:1-5.

Miyaki K, Nishiwaki Y, Maekawa K, Ogawa Y, Asukai N, Yoshimura K, Etoh N, Matsumoto Y, Kikuchi Y, Kumagai N, Omae K. (2005) Effects of sarin on the nervous system of subway workers seven years after the Tokyo subway sarin attack. *J Occup Health.* 47:299-304.

Moran LB, Hickey L, Michael GJ, Derkacs M, Christian LM, Kalaitzakis ME, Pearce RK, Graeber MB. (2008) Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies. *Acta Neuropathol* 115:471-8.

Morris M, Key MP, Farah V. (2007) Sarin produces delayed cardiac and central autonomic changes. *Exp Neurol.* 203:110-5.

- Nishiwaki Y, Maekawa K, Ogawa Y, Asukai N, Minami M, Omae K (2001) Effects of sarin on the nervous system in rescue team staff members and police officers 3 years after the Tokyo subway sarin attack. *Environ Health Perspect.* 109:1169-73.
- Pant SC, Vijayaraghavan R, Das Gupta S. (1993) Sarin induced lung pathology and protection by standard therapy regime. *Biomed Environ Sci.* 6:103-11.
- Rickett DL, Glenn JF, Beers ET. (1986) Central respiratory effects versus neuromuscular actions of nerve agents. *Neurotoxicology* 7:225-36.
- Shih TM, Hulet SW, McDonough JH. (2006) The effects of repeated low-dose sarin exposure. *Toxicol Appl Pharmacol* 215:119-34.
- Singer AW, Jaax NK, Graham JS, McLeod CG Jr. (1987) Cardiomyopathy in Soman and Sarin intoxicated rats. *Toxicol Lett.* 36:243-9.
- Soto A, Delraso NJ, Schlager JJ, Chan VT. (2008) D-Serine exposure resulted in gene expression changes indicative of activation of fibrogenic pathways and down-regulation of energy metabolism and oxidative stress response. *Toxicology.* 243:177-92.
- Stapleton AR, and Chan VT. (2009) Subtoxic chlorpyrifos treatment resulted in differential expression of genes implicated in neurological functions and development. *Arch Toxicol* 83:319-33.
- Svensson I, Waara L, Johansson L, Bucht A, Cassel G. (2001) Soman-induced interleukin-1 beta mRNA and protein in rat brain. *Neurotoxicology* 22:355-62.
- Torres-Altora MI, Mathur BN, Drerup JM, Thomas R, Lovinger DM, O'Callaghan JP, Bibb JA. (2011) Organophosphates dysregulate dopamine signaling, glutamatergic neurotransmission, and induce neuronal injury markers in striatum. *J Neurochem* 119:303-13.
- Yanagisawa N, Morita H, Nakajima T. (2006) Sarin experiences in Japan: acute toxicity and long-term effects. *J Neurol Sci* 249:76-85.
- Yokoyama K, Araki S, Murata K, Nishikitani M, Okumura T and Ishimatsu S. (1998) Chronic neurobehavioral effects of Tokyo subway sarin poisoning in relation to posttraumatic stress disorder, *Arch Environ Health* 53 (1998), pp. 2489–2560.

## 7. LIST OF SYMBOLS, ABBREVIATIONS, AND ACRONYMS

A<sub>260</sub> – Absorbance at 260 nm  
A<sub>280</sub> – Absorbance at 280 nm  
AChE - Acetylcholinesterase  
AGCC – Affymetrix GeneChip Command Console  
BuChE - Butyrylcholinesterase  
DAVID - Database for Annotation, Visualization, and Integrated Discovery  
DTRA - Defense Threats Reduction Agency  
ER - Endoplasmic reticulum  
FOB - Functional observational battery  
GnRH - Gonadotropin-releasing hormone  
GST - Glutathione S-transferase  
IACUC - Institutional Animal Care and Use Committee  
IL - Interleukin  
LD50 - Mean Lethal Dose  
OP - Organophosphorus  
PD - Parkinson's disease  
RPM - Revolutions per minute  
SOM - Self-organizing map  
WSU - Wright State University  
WT - Whole transcript

## 8. Appendix – Supplemental Data

**Supplemental Table 1: FOB Scores of Control and Sarin-Treated Animals.<sup>1, 2</sup>**

| Observation Time Point<br>(post-injection, Hr) | Sacrifice Time Point<br>(post-injection) | Dose<br>(xLD50) | FOB Score<br>(average) | % of Max. Score<br>(average) | St. Error |
|------------------------------------------------|------------------------------------------|-----------------|------------------------|------------------------------|-----------|
| 0.5                                            | 12 Hours                                 | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 7.6                    | 36%*                         | 1%        |
|                                                |                                          | 0.6             | 7.7                    | 37%*                         | 1%        |
|                                                |                                          | 0.75            | 13.0                   | 62%*                         | 5%        |
|                                                | 2 Days                                   | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.6             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.75            | 15.5                   | 74%*                         | 4%        |
|                                                | 5 Days                                   | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.6             | 7.7                    | 37%                          | 2%        |
|                                                |                                          | 0.75            | 15.8                   | 75%*                         | 2%        |
|                                                | 10 Days                                  | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.6             | 6.2                    | 29%                          | 0%        |
|                                                |                                          | 0.75            | 17.6                   | 84%*                         | 1%        |
|                                                | 25 Days                                  | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.4                    | 30%                          | 1%        |
|                                                |                                          | 0.6             | 6.8                    | 33%*                         | 1%        |
|                                                |                                          | 0.75            | 16.5                   | 79%*                         | 5%        |
| 1                                              | 2 Hours                                  | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.6             | 7.0                    | 34%                          | 1%        |
|                                                |                                          | 0.75            | 16.0                   | 78%*                         | 5%        |
|                                                | 6 Hours                                  | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.6             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.75            | 14.0                   | 67%*                         | 4%        |
|                                                | 24 Hours                                 | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.0                    | 30%                          | 1%        |
|                                                |                                          | 0.6             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.75            | 14.0                   | 65%*                         | 5%        |
|                                                | 2 Days                                   | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.6             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.75            | 16.0                   | 77%*                         | 4%        |
|                                                | 5 Days                                   | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.6             | 8.0                    | 37%                          | 2%        |
|                                                |                                          | 0.75            | 14.0                   | 67%*                         | 3%        |
|                                                | 10 Days                                  | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.6             | 6.0                    | 30%                          | 1%        |
|                                                |                                          | 0.75            | 17.0                   | 80%*                         | 2%        |
|                                                | 25 Days                                  | 0               | 6.0                    | 29%                          | 0%        |
|                                                |                                          | 0.4             | 7.0                    | 32%*                         | 1%        |
|                                                |                                          | 0.6             | 7.0                    | 33%*                         | 1%        |
|                                                |                                          | 0.75            | 15.0                   | 73%*                         | 4%        |
| 4                                              | 6 Hours                                  | 0               | 6.0                    | 29%                          | 0%        |

|         |          |        |      |      |     |    |
|---------|----------|--------|------|------|-----|----|
|         |          | 0.4    | 6.0  | 29%  | 0%  |    |
|         |          | 0.6    | 6.0  | 29%  | 0%  |    |
|         |          | 0.75   | 14.0 | 65%* | 3%  |    |
|         | 12 Hours | 0      | 6.0  | 29%  | 0%  |    |
|         |          | 0.4    | 6.0  | 30%  | 1%  |    |
|         |          | 0.6    | 6.0  | 29%  | 0%  |    |
|         |          | 0.75   | 11.0 | 52%* | 3%  |    |
|         | 24 Hours | 0      | 6.0  | 29%  | 0%  |    |
|         |          | 0.4    | 6.0  | 30%  | 1%  |    |
|         |          | 0.6    | 6.0  | 29%  | 0%  |    |
|         |          | 0.75   | 12.0 | 55%* | 4%  |    |
|         | 2 Days   | 0      | 6.0  | 29%  | 0%  |    |
|         |          | 0.4    | 6.0  | 29%  | 0%  |    |
|         |          | 0.6    | 6.0  | 29%  | 0%  |    |
|         |          | 0.75   | 11.0 | 51%* | 2%  |    |
|         | 5 Days   | 0      | 6.0  | 29%  | 0%  |    |
|         |          | 0.4    | 6.0  | 29%  | 0%  |    |
|         |          | 0.6    | 6.0  | 29%  | 0%  |    |
|         |          | 0.75   | 9.0  | 43%* | 3%  |    |
|         | 10 Days  | 0      | 6.0  | 29%  | 0%  |    |
|         |          | 0.4    | 6.0  | 29%  | 0%  |    |
|         |          | 0.6    | 6.0  | 30%  | 1%  |    |
|         |          | 0.75   | 13.0 | 63%* | 2%  |    |
|         | 25 Days  | 0      | 6.0  | 29%  | 0%  |    |
|         |          | 0.4    | 7.0  | 31%  | 1%  |    |
|         |          | 0.6    | 7.0  | 35%* | 1%  |    |
|         |          | 0.75   | 9.0  | 42%* | 1%  |    |
|         | 24       | 2 Days | 0    | 6.0  | 29% | 0% |
|         |          |        | 0.4  | 6.0  | 29% | 0% |
|         |          |        | 0.6  | 6.0  | 29% | 0% |
|         |          |        | 0.75 | 6.0  | 30% | 0% |
|         |          | 5 Days | 0    | 6.0  | 29% | 0% |
| 0.4     |          |        | 6.0  | 29%  | 0%  |    |
| 0.6     |          |        | 6.0  | 29%  | 0%  |    |
| 0.75    |          |        | 6.0  | 29%  | 0%  |    |
| 10 Days |          | 0      | 6.0  | 29%  | 0%  |    |
|         |          | 0.4    | 6.0  | 29%  | 0%  |    |
|         |          | 0.6    | 6.0  | 29%  | 0%  |    |
|         |          | 0.75   | 6.0  | 29%  | 0%  |    |
| 25 Days |          | 0      | 6.0  | 29%  | 0%  |    |
|         |          | 0.4    | 6.0  | 29%  | 0%  |    |
|         |          | 0.6    | 6.0  | 29%  | 0%  |    |
|         |          | 0.75   | 6.0  | 29%  | 0%  |    |

<sup>1</sup>The FOB scores of the control and sarin-treated animals at 0.5, 1, 4 and 24 hours post-treatment are shown.

<sup>2</sup>Data of several experiments (2-hr, 6-hr and 24-hr time points for observation at 0.5 hour; 12-hr time point experiment for observation at 1 hour; 2-hr time point experiment for observation at 4 hours; 2-, 6-, 12- and 24-hour time point experiments for observation at 24 hours) were not available.

\*Significant changes in observational functions ( $p < 0.05$ ).

**Supplemental Table 2: Sarin-Induced Inhibition of AChE in Frontal Lobe.**

| Time Point | Sarin Dose | AChE Activity (nmoles/min/ $\mu$ L) |           |           |
|------------|------------|-------------------------------------|-----------|-----------|
|            |            | Average                             | St. Error | % Control |
| 2 hours    | Control    | 11.45                               | 0.72      | 100%      |
|            | 0.4x LD50  | 10.02                               | 0.41      | 88%       |
|            | 0.6x LD50  | 4.29                                | 0.35      | 37%*      |
|            | 0.75x LD50 | 2.17                                | 0.16      | 19%*      |
| 6 hours    | Control    | 10.32                               | 0.72      | 100%      |
|            | 0.4x LD50  | 8.70                                | 0.22      | 84%       |
|            | 0.6x LD50  | 5.46                                | 0.14      | 53%*      |
|            | 0.75x LD50 | 3.14                                | 0.12      | 30%*      |
| 12 hours   | Control    | 9.89                                | 0.60      | 100%      |
|            | 0.4x LD50  | 9.93                                | 0.41      | 100%      |
|            | 0.6x LD50  | 6.40                                | 0.29      | 65%*      |
|            | 0.75x LD50 | 3.24                                | 0.16      | 33%*      |
| 24 hours   | Control    | 11.19                               | 0.11      | 100%      |
|            | 0.4x LD50  | 9.84                                | 0.16      | 88%*      |
|            | 0.6x LD50  | 7.18                                | 0.35      | 64%*      |
|            | 0.75x LD50 | 3.79                                | 0.18      | 34%*      |
| 48 hours   | Control    | 11.40                               | 0.35      | 100%      |
|            | 0.4x LD50  | 9.24                                | 0.36      | 81%*      |
|            | 0.6x LD50  | 7.56                                | 0.25      | 66%*      |
|            | 0.75x LD50 | 4.24                                | 0.21      | 37%*      |
| 120 hours  | Control    | 10.88                               | 0.30      | 100%      |
|            | 0.4x LD50  | 10.85                               | 0.67      | 100%      |
|            | 0.6x LD50  | 6.94                                | 0.22      | 64%*      |
|            | 0.75x LD50 | 4.77                                | 0.22      | 44%*      |
| 240 hours  | Control    | 12.09                               | 1.31      | 100%      |
|            | 0.4x LD50  | 14.98                               | 1.43      | 124%      |
|            | 0.6x LD50  | 8.27                                | 0.17      | 68%       |
|            | 0.75x LD50 | 7.33                                | 0.25      | 61%       |
| 600 hours  | Control    | 10.96                               | 0.46      | 100%      |
|            | 0.4x LD50  | 9.50                                | 0.37      | 87%       |
|            | 0.6x LD50  | 9.05                                | 0.33      | 83%       |
|            | 0.75x LD50 | 8.24                                | 0.21      | 75%*      |

\*Significant changes in enzyme activities ( $p < 0.05$ ).

**Supplemental Table 3: Sarin-Induced Inhibition of Erythrocyte AChE and Plasma BuChE.**

| Time Point | Sarin Dose | AChE Activity (nmoles/min/ $\mu$ L) |           |           | BuChE Activity (nmoles/min/ $\mu$ L) |           |           |
|------------|------------|-------------------------------------|-----------|-----------|--------------------------------------|-----------|-----------|
|            |            | Average                             | St. Error | % Control | Average                              | St. Error | % Control |
| 2 hours    | Control    | 0.48                                | 0.04      | 100%      | 0.59                                 | 0.03      | 100%      |
|            | 0.4x LD50  | 0.19                                | 0.02      | 39%*      | 0.36                                 | 0.03      | 61%*      |
|            | 0.6x LD50  | 0.11                                | 0.01      | 22%*      | 0.26                                 | 0.03      | 43%*      |
|            | 0.75x LD50 | 0.15                                | 0.01      | 31%*      | 0.16                                 | 0.03      | 27%*      |
| 6 hours    | Control    | 0.35                                | 0.02      | 100%      | 0.43                                 | 0.05      | 100%      |
|            | 0.4x LD50  | 0.18                                | 0.03      | 52%*      | 0.41                                 | 0.05      | 96%       |
|            | 0.6x LD50  | 0.11                                | 0.02      | 31%*      | 0.42                                 | 0.02      | 98%       |
|            | 0.75x LD50 | 0.09                                | 0.01      | 25%*      | 0.41                                 | 0.02      | 96%       |
| 12 hour    | Control    | 0.44                                | 0.03      | 100%      | 0.69                                 | 0.03      | 100%      |
|            | 0.4x LD50  | 0.13                                | 0.01      | 29%*      | 0.62                                 | 0.03      | 90%       |
|            | 0.6x LD50  | 0.14                                | 0.02      | 32%*      | 0.61                                 | 0.04      | 89%       |
|            | 0.75x LD50 | 0.15                                | 0.01      | 34%*      | 0.60                                 | 0.01      | 88%       |
| 48 hours   | Control    | 0.28                                | 0.01      | 100%      | 0.66                                 | 0.05      | 100%      |
|            | 0.4x LD50  | 0.24                                | 0.01      | 85%       | 0.60                                 | 0.03      | 91%       |
|            | 0.6x LD50  | 0.21                                | 0.02      | 76%       | 0.47                                 | 0.04      | 71%       |
|            | 0.75x LD50 | 0.24                                | 0.02      | 85%       | 0.50                                 | 0.02      | 76%       |
| 120 hours  | Control    | 0.32                                | 0.02      | 100%      | 0.65                                 | 0.04      | 100%      |
|            | 0.4x LD50  | 0.26                                | 0.02      | 82%       | 0.55                                 | 0.04      | 86%       |
|            | 0.6x LD50  | 0.22                                | 0.02      | 68%*      | 0.53                                 | 0.03      | 82%       |
|            | 0.75x LD50 | 0.22                                | 0.02      | 69%*      | 0.50                                 | 0.01      | 77%       |
| 600 hours  | Control    | 0.29                                | 0.02      | 100%      | 0.64                                 | 0.04      | 100%      |
|            | 0.4x LD50  | 0.24                                | 0.03      | 83%       | 0.70                                 | 0.02      | 110%      |
|            | 0.6x LD50  | 0.27                                | 0.02      | 93%       | 0.65                                 | 0.02      | 102%      |
|            | 0.75x LD50 | 0.32                                | 0.01      | 111%      | 0.58                                 | 0.02      | 91%       |


\*Significant changes in enzyme activities ( $p < 0.05$ ).

**Supplemental Table 4: Sarin-Induced Hippocampal Differential Gene Expression.**


| Time after Sarin Treatment (Hr)                | 2   | 6    | 12   | 24  | 48  | 120 | 240 | 600  |
|------------------------------------------------|-----|------|------|-----|-----|-----|-----|------|
| Up-regulated Genes                             | 275 | 1866 | 469  | 372 | 552 | 836 | 73  | 1684 |
| Down-regulation Genes                          | 129 | 231  | 853  | 248 | 292 | 47  | 457 | 78   |
| Total Number of Differentially Expressed Genes | 404 | 2097 | 1322 | 620 | 844 | 883 | 530 | 1762 |

## Supplemental Figure 1: Self-Organizing Maps of Differentially Expressed Genes


### A. 2 Hours




## B. 6 Hours




### C. 12 Hours




## D. 24 Hours




## E. 2 Days




## F. 5 Days



## G. 10 Days



## H. 25 Days



**Supplemental Table 5: Complete Lists of Pathways Showing Perturbation (Significant Enrichment of Differentially Expressed Genes)**

**A. 2 Hours**

| Biological Process and Pathway                    | Count | Change Direction |
|---------------------------------------------------|-------|------------------|
| mRNA metabolic process                            | 17    | Up-regulation    |
| mRNA processing                                   | 14    | Up-regulation    |
| regulation of mRNA stability                      | 3     | Up-regulation    |
| RNA splicing                                      | 10    | Up-regulation    |
| Spliceosome                                       | 9     | Up-regulation    |
| ribonucleoprotein complex                         | 15    | Up-regulation    |
| programmed cell death                             | 13    | Up-regulation    |
| positive regulation of programmed cell death      | 8     | Up-regulation    |
| regulation of programmed cell death               | 16    | Up-regulation    |
| regulation of cell proliferation                  | 16    | Up-regulation    |
| positive regulation of cell proliferation         | 9     | Up-regulation    |
| negative regulation of cell proliferation         | 8     | Up-regulation    |
| negative regulation of cell differentiation       | 8     | Up-regulation    |
| amino acid transport                              | 6     | Up-regulation    |
| vasculature development                           | 9     | Up-regulation    |
| endoplasmic reticulum                             | 22    | Up-regulation    |
| ubl conjugation                                   | 19    | Up-regulation    |
| lysosome                                          | 4     | Down-regulation  |
| lytic vacuole                                     | 4     | Down-regulation  |
| ribosome                                          | 6     | Down-regulation  |
| ribonucleoprotein complex                         | 7     | Down-regulation  |
| ribosomal protein                                 | 6     | Down-regulation  |
| oxidative phosphorylation                         | 4     | Down-regulation  |
| posttranscriptional regulation of gene expression | 8     | N/A*             |

\*N/A – Not applicable, result obtained by combining up- and down-regulated genes.

## B. 6 Hours

| Biological Process and Pathway                                   | Count | Change Direction |
|------------------------------------------------------------------|-------|------------------|
| transcription                                                    | 218   | Up-regulation    |
| transcription regulation                                         | 177   | Up-regulation    |
| posttranscriptional regulation of gene expression                | 31    | Up-regulation    |
| mRNA processing                                                  | 54    | Up-regulation    |
| RNA splicing                                                     | 37    | Up-regulation    |
| translation                                                      | 45    | Up-regulation    |
| regulation of translation                                        | 22    | Up-regulation    |
| regulation of eIF4e and p70 S6 Kinase                            | 8     | Up-regulation    |
| negative regulation of translation                               | 8     | Up-regulation    |
| protein localization                                             | 107   | Up-regulation    |
| establishment of protein localization                            | 87    | Up-regulation    |
| maintenance of protein location in cell                          | 7     | Up-regulation    |
| protein localization in mitochondrion                            | 6     | Up-regulation    |
| protein transport                                                | 86    | Up-regulation    |
| intracellular protein transport                                  | 46    | Up-regulation    |
| vesicle-mediated transport                                       | 61    | Up-regulation    |
| protein import                                                   | 14    | Up-regulation    |
| protein targeting                                                | 25    | Up-regulation    |
| protein targeting to mitochondrion                               | 6     | Up-regulation    |
| negative regulation of protein complex disassembly               | 8     | Up-regulation    |
| cellular protein catabolic process                               | 100   | Up-regulation    |
| ubiquitin-dependent protein catabolic process                    | 35    | Up-regulation    |
| generation of precursor metabolites and energy                   | 33    | Up-regulation    |
| mitochondrion organization                                       | 16    | Up-regulation    |
| electron transport chain                                         | 17    | Up-regulation    |
| peroxisome organization                                          | 6     | Up-regulation    |
| phospholipid biosynthetic process                                | 14    | Up-regulation    |
| cytoskeleton organization                                        | 40    | Up-regulation    |
| regulation of cytoskeleton organization                          | 18    | Up-regulation    |
| microtubule-based process                                        | 29    | Up-regulation    |
| regulation of microtubule cytoskeleton organization              | 9     | Up-regulation    |
| regulation of microtubule depolymerization                       | 5     | Up-regulation    |
| negative regulation of microtubule depolymerization              | 5     | Up-regulation    |
| cellular response to stress                                      | 51    | Up-regulation    |
| response to DNA damage stimulus                                  | 37    | Up-regulation    |
| DNA repair                                                       | 30    | Up-regulation    |
| cellular response to insulin stimulus                            | 9     | Up-regulation    |
| Signaling Pathway from G-Protein Families                        | 10    | Up-regulation    |
| transmembrane receptor protein tyrosine kinase signaling pathway | 32    | Up-regulation    |
| cell cycle                                                       | 69    | Up-regulation    |
| cell motion                                                      | 44    | Up-regulation    |
| cell migration                                                   | 32    | Up-regulation    |
| neuron projection development                                    | 34    | Up-regulation    |
| neuron projection morphogenesis                                  | 25    | Up-regulation    |
| cell morphogenesis involved in neuron differentiation            | 24    | Up-regulation    |
| axonogenesis                                                     | 23    | Up-regulation    |
| dendrite development                                             | 11    | Up-regulation    |
| synaptogenesis                                                   | 6     | Up-regulation    |
| regulation of long-term neuronal synaptic plasticity             | 9     | Up-regulation    |
| synaptic transmission                                            | 31    | Up-regulation    |

|                                            |     |                 |
|--------------------------------------------|-----|-----------------|
| adult locomotory behavior                  | 11  | Up-regulation   |
| learning or memory                         | 15  | Up-regulation   |
| learning                                   | 12  | Up-regulation   |
| transmission of nerve impulse              | 36  | Up-regulation   |
| regulation of synaptic transmission        | 17  | Up-regulation   |
| regulation of neuronal synaptic plasticity | 11  | Up-regulation   |
| nerve-nerve synaptic transmission          | 9   | Up-regulation   |
| synaptic transmission, glutamatergic       | 5   | Up-regulation   |
| glycerophospholipid biosynthetic process   | 9   | Up-regulation   |
| phosphatidylcholine biosynthetic process   | 4   | Up-regulation   |
| regulation of sequestering of triglyceride | 3   | Up-regulation   |
| potassium ion transport                    | 22  | Up-regulation   |
| regulation of membrane potential           | 19  | Up-regulation   |
| spliceosome                                | 5   | Down-regulation |
| mitochondrion                              | 23  | Down-regulation |
| endoplasmic reticulum                      | 19  | Down-regulation |
| lysosome                                   | 6   | Down-regulation |
| lytic vacuole                              | 6   | Down-regulation |
| lipid synthesis                            | 5   | Down-regulation |
| synaptosome                                | 3   | Down-regulation |
| gene silencing                             | 12  | N/A*            |
| mRNA splicing                              | 41  | N/A*            |
| mRNA transport                             | 12  | N/A*            |
| ribosome                                   | 35  | N/A*            |
| ribosomal protein                          | 33  | N/A*            |
| protein biosynthesis                       | 26  | N/A*            |
| translation regulation                     | 17  | N/A*            |
| endomembrane system                        | 71  | N/A*            |
| Golgi apparatus                            | 83  | N/A*            |
| ER-Golgi transport                         | 14  | N/A*            |
| vesicle                                    | 65  | N/A*            |
| vesicle-mediated transport                 | 67  | N/A*            |
| chaperone                                  | 24  | N/A*            |
| ubl conjugation pathway                    | 88  | N/A*            |
| ubiquitin mediated proteolysis             | 23  | N/A*            |
| proteasome complex                         | 18  | N/A*            |
| mitochondrion                              | 165 | N/A*            |
| electron transport                         | 16  | N/A*            |
| cytoskeleton                               | 133 | N/A*            |
| regulation of actin cytoskeleton           | 29  | N/A*            |
| microtubule cytoskeleton                   | 59  | N/A*            |
| microtubule                                | 31  | N/A*            |
| microtubule cytoskeleton organization      | 21  | N/A*            |
| dynein complex                             | 10  | N/A*            |
| DNA damage                                 | 28  | N/A*            |
| apoptosis                                  | 46  | N/A*            |
| cell-cell signaling                        | 39  | N/A*            |
| Neurotrophin signaling pathway             | 23  | N/A*            |
| ErbB signaling pathway                     | 18  | N/A*            |
| Insulin signaling pathway                  | 29  | N/A*            |
| MAPK signaling pathway                     | 41  | N/A*            |
| mTOR signaling pathway                     | 12  | N/A*            |
| neurogenesis                               | 22  | N/A*            |

|                        |    |      |
|------------------------|----|------|
| focal adhesion         | 33 | N/A* |
| adherens junction      | 14 | N/A* |
| neuron projection      | 44 | N/A* |
| axon guidance          | 21 | N/A* |
| dendrite               | 21 | N/A* |
| synapse                | 54 | N/A* |
| synapse organization   | 10 | N/A* |
| postsynaptic membrane  | 24 | N/A* |
| postsynaptic density   | 15 | N/A* |
| presynaptic membrane   | 9  | N/A* |
| Alzheimer's disease    | 28 | N/A* |
| Glioma                 | 14 | N/A* |
| Long-term potentiation | 21 | N/A* |
| Long-term depression   | 14 | N/A* |

\*N/A – Not applicable, result obtained by combining up- and down-regulated genes.

### C. 12 Hours

| Biological Process and Pathway                                   | Count | Change Direction |
|------------------------------------------------------------------|-------|------------------|
| mRNA metabolic process                                           | 20    | Up-regulation    |
| mRNA processing                                                  | 18    | Up-regulation    |
| RNA splicing                                                     | 17    | Up-regulation    |
| establishment of RNA localization                                | 7     | Up-regulation    |
| mRNA transport                                                   | 6     | Up-regulation    |
| ribonucleoprotein complex                                        | 28    | Up-regulation    |
| regulation of translation                                        | 7     | Up-regulation    |
| cellular protein catabolic process                               | 27    | Up-regulation    |
| proteasome complex                                               | 7     | Up-regulation    |
| protein catabolic process                                        | 29    | Up-regulation    |
| ubl conjugation pathway                                          | 20    | Up-regulation    |
| ubiquitin-dependent protein catabolic process                    | 14    | Up-regulation    |
| cytoskeletal part                                                | 25    | Up-regulation    |
| regulation of actin cytoskeleton                                 | 11    | Up-regulation    |
| actin cytoskeleton organization                                  | 9     | Up-regulation    |
| enzyme linked receptor protein signaling pathway                 | 15    | Up-regulation    |
| MAPK signaling pathway                                           | 16    | Up-regulation    |
| transforming growth factor beta receptor signaling pathway       | 5     | Up-regulation    |
| neuron projection                                                | 10    | Up-regulation    |
| dendrite                                                         | 8     | Up-regulation    |
| dendritic spine                                                  | 4     | Up-regulation    |
| dendritic shaft                                                  | 3     | Up-regulation    |
| synapse                                                          | 20    | Up-regulation    |
| synapse part                                                     | 14    | Up-regulation    |
| presynaptic membrane                                             | 6     | Up-regulation    |
| postsynaptic membrane                                            | 10    | Up-regulation    |
| postsynaptic density                                             | 8     | Up-regulation    |
| neurogenesis                                                     | 8     | Up-regulation    |
| regulation of neuron differentiation                             | 6     | Up-regulation    |
| learning or memory                                               | 8     | Up-regulation    |
| learning                                                         | 5     | Up-regulation    |
| memory                                                           | 4     | Up-regulation    |
| synaptic transmission                                            | 12    | Up-regulation    |
| regulation of synaptic transmission                              | 9     | Up-regulation    |
| regulation of synaptic plasticity                                | 5     | Up-regulation    |
| neurotransmitter secretion                                       | 5     | Up-regulation    |
| vasculature development                                          | 13    | Up-regulation    |
| respiratory chain                                                | 5     | Up-regulation    |
| cell-cell signaling                                              | 14    | Up-regulation    |
| transmembrane receptor protein tyrosine kinase signaling pathway | 10    | Up-regulation    |
| wnt signaling pathway                                            | 7     | Up-regulation    |
| regulation of transcription                                      | 105   | Down-regulation  |
| negative regulation of transcription, DNA-dependent              | 20    | Down-regulation  |
| transcription corepressor activity                               | 7     | Down-regulation  |
| RNA processing                                                   | 26    | Down-regulation  |
| mRNA processing                                                  | 19    | Down-regulation  |
| RNA splicing                                                     | 16    | Down-regulation  |
| negative regulation of RNA metabolic process                     | 20    | Down-regulation  |
| cytoplasmic vesicle                                              | 31    | Down-regulation  |
| protein transport                                                | 44    | Down-regulation  |

|                                                        |    |                 |
|--------------------------------------------------------|----|-----------------|
| endoplasmic reticulum                                  | 43 | Down-regulation |
| Golgi apparatus                                        | 41 | Down-regulation |
| trans-Golgi network                                    | 9  | Down-regulation |
| vesicle                                                | 32 | Down-regulation |
| regulation of protein ubiquitination                   | 5  | Down-regulation |
| chromatin modification                                 | 17 | Down-regulation |
| histone modification                                   | 10 | Down-regulation |
| H4/H2A histone acetyltransferase complex               | 5  | Down-regulation |
| histone H2A acetylation                                | 4  | Down-regulation |
| histone H4 acetylation                                 | 4  | Down-regulation |
| Glutathione S-transferase, C-terminal                  | 7  | Down-regulation |
| Glutathione S-transferase, Mu class                    | 4  | Down-regulation |
| Glutathione S-transferase, N-terminal                  | 7  | Down-regulation |
| Glutathione S-transferase, C-terminal-like             | 5  | Down-regulation |
| Glutathione S-transferase/chloride channel, C-terminal | 8  | Down-regulation |
| Metabolism of xenobiotics by cytochrome P450           | 8  | Down-regulation |
| mitochondrion                                          | 71 | Down-regulation |
| mitochondrial lumen                                    | 14 | Down-regulation |
| mitochondrial matrix                                   | 14 | Down-regulation |
| microtubule-based movement                             | 8  | Down-regulation |
| endocytosis                                            | 13 | Down-regulation |
| regulation of endocytosis                              | 6  | Down-regulation |
| response to nutrient levels                            | 11 | Down-regulation |
| glucose metabolic process                              | 11 | Down-regulation |
| carbohydrate biosynthetic process                      | 8  | Down-regulation |
| Arginine and proline metabolism                        | 7  | Down-regulation |
| response to temperature stimulus                       | 7  | Down-regulation |
| cell cycle                                             | 36 | Down-regulation |
| regulation of growth                                   | 19 | Down-regulation |
| positive regulation of cell differentiation            | 14 | Down-regulation |
| cerebral cortex neuron differentiation                 | 3  | Down-regulation |
| potassium channel complex                              | 8  | Down-regulation |
| voltage-gated potassium channel complex                | 8  | Down-regulation |
| ribonucleoprotein complex                              | 30 | Down-regulation |
| membrane lipid metabolic process                       | 7  | Down-regulation |
| membrane lipid catabolic process                       | 4  | Down-regulation |
| sphingolipid catabolic process                         | 4  | Down-regulation |
| androgen receptor signaling pathway                    | 3  | Down-regulation |
| intracellular receptor-mediated signaling pathway      | 6  | Down-regulation |
| steroid hormone receptor signaling pathway             | 5  | Down-regulation |
| vesicle-mediated transport                             | 41 | N/A*            |
| membrane invagination                                  | 20 | N/A*            |
| histone acetyltransferase complex                      | 8  | N/A*            |
| regulation of cell cycle                               | 20 | N/A*            |
| cell cycle arrest                                      | 8  | N/A*            |
| regulation of neurogenesis                             | 14 | N/A*            |
| forebrain neuron differentiation                       | 4  | N/A*            |

\*N/A – Not applicable, result obtained by combining up- and down-regulated genes.

## D. 24 Hours

| Biological Process and Pathway                                       | Count | Change Direction |
|----------------------------------------------------------------------|-------|------------------|
| positive regulation of gene expression                               | 17    | Up-regulation    |
| negative regulation of gene expression                               | 14    | Up-regulation    |
| positive regulation of transcription                                 | 17    | Up-regulation    |
| negative regulation of transcription                                 | 13    | Up-regulation    |
| regulation of transcription, DNA-dependent                           | 35    | Up-regulation    |
| positive regulation of transcription, DNA-dependent                  | 16    | Up-regulation    |
| negative regulation of transcription, DNA-dependent                  | 12    | Up-regulation    |
| regulation of transcription from RNA polymerase II promoter          | 21    | Up-regulation    |
| positive regulation of transcription from RNA polymerase II promoter | 13    | Up-regulation    |
| negative regulation of transcription from RNA polymerase II promoter | 11    | Up-regulation    |
| positive regulation of RNA metabolic process                         | 16    | Up-regulation    |
| cell-cell signaling                                                  | 13    | Up-regulation    |
| MAPK signaling pathway                                               | 12    | Up-regulation    |
| vasculature development                                              | 9     | Up-regulation    |
| blood vessel morphogenesis                                           | 8     | Up-regulation    |
| wound healing                                                        | 8     | Up-regulation    |
| angiogenesis                                                         | 6     | Up-regulation    |
| regulation of cell proliferation                                     | 17    | Up-regulation    |
| positive regulation of cell proliferation                            | 12    | Up-regulation    |
| regulation of growth                                                 | 10    | Up-regulation    |
| negative regulation of cell differentiation                          | 9     | Up-regulation    |
| neuron differentiation                                               | 14    | Up-regulation    |
| regulation of neurogenesis                                           | 8     | Up-regulation    |
| regulation of cell death                                             | 17    | Up-regulation    |
| regulation of apoptosis                                              | 17    | Up-regulation    |
| positive regulation of cell death                                    | 10    | Up-regulation    |
| positive regulation of apoptosis                                     | 10    | Up-regulation    |
| axon                                                                 | 5     | Up-regulation    |
| regulation of neuron projection development                          | 4     | Up-regulation    |
| synapse                                                              | 13    | Up-regulation    |
| synapse part                                                         | 9     | Up-regulation    |
| postsynaptic density                                                 | 4     | Up-regulation    |
| transmission of nerve impulse                                        | 9     | Up-regulation    |
| regulation of synaptic transmission                                  | 6     | Up-regulation    |
| regulation of excitatory postsynaptic membrane potential             | 3     | Up-regulation    |
| regulation of neuronal synaptic plasticity                           | 3     | Up-regulation    |
| ion transport                                                        | 15    | Up-regulation    |
| vitamin A metabolic process                                          | 5     | Up-regulation    |
| response to insulin stimulus                                         | 4     | Up-regulation    |
| response to dietary excess                                           | 3     | Up-regulation    |
| regulation of hormone levels                                         | 9     | Up-regulation    |
| actin cytoskeleton                                                   | 8     | Up-regulation    |
| regulation of membrane potential                                     | 6     | Up-regulation    |
| regulation of calcium ion transport                                  | 4     | Up-regulation    |
| positive regulation of transcription from RNA polymerase II promoter | 9     | Down-regulation  |
| posttranscriptional regulation of gene expression                    | 7     | Down-regulation  |
| translation regulation                                               | 4     | Down-regulation  |

|                                                      |    |                 |
|------------------------------------------------------|----|-----------------|
| Golgi apparatus                                      | 20 | Down-regulation |
| trans-Golgi network                                  | 4  | Down-regulation |
| regulation of protein localization                   | 5  | Down-regulation |
| cytoplasmic membrane-bounded vesicle                 | 12 | Down-regulation |
| cytoplasmic vesicle                                  | 18 | Down-regulation |
| vesicle                                              | 18 | Down-regulation |
| vesicle-mediated transport                           | 11 | Down-regulation |
| mitochondrial envelope                               | 11 | Down-regulation |
| mitochondrial part                                   | 13 | Down-regulation |
| mitochondrial inner membrane                         | 9  | Down-regulation |
| generation of precursor metabolites and energy       | 8  | Down-regulation |
| MAPK signaling pathway                               | 8  | Down-regulation |
| negative regulation of MAP kinase activity           | 3  | Down-regulation |
| actin filament bundle                                | 3  | Down-regulation |
| regulation of angiogenesis                           | 4  | Down-regulation |
| myelination                                          | 3  | Down-regulation |
| synaptosome                                          | 5  | Down-regulation |
| regulation of membrane potential                     | 6  | Down-regulation |
| ion transport                                        | 16 | Down-regulation |
| regulation of cell adhesion                          | 6  | Down-regulation |
| growth cone                                          | 4  | Down-regulation |
| site of polarized growth                             | 4  | Down-regulation |
| negative regulation of cell adhesion                 | 3  | Down-regulation |
| regulation of protein transport                      | 6  | N/A*            |
| protein kinase cascade                               | 14 | N/A*            |
| regulation of protein kinase cascade                 | 10 | N/A*            |
| response to wounding                                 | 18 | N/A*            |
| cell migration                                       | 15 | N/A*            |
| cell motility                                        | 15 | N/A*            |
| axon ensheathment                                    | 6  | N/A*            |
| dendrite                                             | 8  | N/A*            |
| dendritic spine                                      | 4  | N/A*            |
| regulation of dendrite development                   | 3  | N/A*            |
| regulation of action potential                       | 6  | N/A*            |
| regulation of action potential in neuron             | 6  | N/A*            |
| regulation of postsynaptic membrane potential        | 4  | N/A*            |
| regulation of long-term neuronal synaptic plasticity | 4  | N/A*            |
| sodium ion transport                                 | 10 | N/A*            |
| regulation of ion transport                          | 6  | N/A*            |

\*N/A – Not applicable, result obtained by combining up- and down-regulated genes.

## E. 48 hours

| Biological Process and Pathway                             | Count | Change Direction |
|------------------------------------------------------------|-------|------------------|
| regulation of transcription, DNA-dependent                 | 46    | Up-regulation    |
| negative regulation of transcription                       | 15    | Up-regulation    |
| RNA splicing                                               | 11    | Up-regulation    |
| spliceosome                                                | 7     | Up-regulation    |
| protein folding                                            | 8     | Up-regulation    |
| proteolysis                                                | 39    | Up-regulation    |
| proteolysis involved in cellular protein catabolic process | 28    | Up-regulation    |
| ubiquitin-proteasome pathway                               | 24    | Up-regulation    |
| ubiquitin-dependent protein catabolic process              | 11    | Up-regulation    |
| proteasome complex                                         | 6     | Up-regulation    |
| proteasome                                                 | 5     | Up-regulation    |
| nuclear envelope-endoplasmic reticulum network             | 10    | Up-regulation    |
| endoplasmic reticulum part                                 | 13    | Up-regulation    |
| endoplasmic reticulum membrane                             | 9     | Up-regulation    |
| cholesterol biosynthetic process                           | 7     | Up-regulation    |
| lipid synthesis                                            | 14    | Up-regulation    |
| steroid biosynthetic process                               | 9     | Up-regulation    |
| sterol biosynthetic process                                | 8     | Up-regulation    |
| cell-cell signaling                                        | 18    | Up-regulation    |
| MAPK signaling pathway                                     | 12    | Up-regulation    |
| TGF-beta signaling pathway                                 | 7     | Up-regulation    |
| Neurotrophin signaling pathway                             | 8     | Up-regulation    |
| response to hormone stimulus                               | 9     | Up-regulation    |
| response to peptide hormone stimulus                       | 7     | Up-regulation    |
| response to insulin stimulus                               | 5     | Up-regulation    |
| regulation of centrosome duplication                       | 3     | Up-regulation    |
| cell morphogenesis involved in differentiation             | 15    | Up-regulation    |
| cell morphogenesis involved in neuron differentiation      | 14    | Up-regulation    |
| regulation of cell growth                                  | 7     | Up-regulation    |
| positive regulation of cell growth                         | 4     | Up-regulation    |
| regulation of neurogenesis                                 | 10    | Up-regulation    |
| forebrain development                                      | 10    | Up-regulation    |
| cell proliferation in forebrain                            | 3     | Up-regulation    |
| hindbrain development                                      | 5     | Up-regulation    |
| neuron development                                         | 20    | Up-regulation    |
| neuron differentiation                                     | 23    | Up-regulation    |
| regulation of neuron differentiation                       | 10    | Up-regulation    |
| neuron maturation                                          | 3     | Up-regulation    |
| regulation of cell size                                    | 9     | Up-regulation    |
| positive regulation of cell size                           | 4     | Up-regulation    |
| multicellular organismal response to stress                | 5     | Up-regulation    |
| regulation of cell death                                   | 23    | Up-regulation    |
| regulation of apoptosis                                    | 23    | Up-regulation    |
| regulation of neuron apoptosis                             | 8     | Up-regulation    |
| negative regulation of neuron apoptosis                    | 7     | Up-regulation    |
| cell projection organization                               | 19    | Up-regulation    |
| regulation of cell projection organization                 | 6     | Up-regulation    |
| neuron projection development                              | 17    | Up-regulation    |
| regulation of neuron projection development                | 6     | Up-regulation    |
| neuron projection morphogenesis                            | 14    | Up-regulation    |

|                                                             |    |                 |
|-------------------------------------------------------------|----|-----------------|
| microtubule organizing center                               | 10 | Up-regulation   |
| regulation of cytoskeleton organization                     | 7  | Up-regulation   |
| axonogenesis                                                | 13 | Up-regulation   |
| axon guidance                                               | 9  | Up-regulation   |
| regulation of axonogenesis                                  | 5  | Up-regulation   |
| positive regulation of axonogenesis                         | 3  | Up-regulation   |
| regulation of axon extension                                | 3  | Up-regulation   |
| dendrite development                                        | 6  | Up-regulation   |
| synapse                                                     | 17 | Up-regulation   |
| synapse part                                                | 11 | Up-regulation   |
| transmission of nerve impulse                               | 14 | Up-regulation   |
| regulation of transmission of nerve impulse                 | 9  | Up-regulation   |
| positive regulation of transmission of nerve impulse        | 3  | Up-regulation   |
| synaptic transmission                                       | 11 | Up-regulation   |
| regulation of synaptic transmission                         | 8  | Up-regulation   |
| positive regulation of synaptic transmission                | 3  | Up-regulation   |
| regulation of synaptic plasticity                           | 6  | Up-regulation   |
| Long-term potentiation                                      | 6  | Up-regulation   |
| learning or memory                                          | 8  | Up-regulation   |
| memory                                                      | 6  | Up-regulation   |
| fear response                                               | 4  | Up-regulation   |
| sensory perception of pain                                  | 5  | Up-regulation   |
| ion channel activity                                        | 16 | Up-regulation   |
| calcium channel activity                                    | 6  | Up-regulation   |
| calcium-activated potassium channel activity                | 3  | Up-regulation   |
| regulation of microtubule-based process                     | 7  | Up-regulation   |
| regulation of microtubule cytoskeleton organization         | 5  | Up-regulation   |
| transcription cofactor activity                             | 7  | Down-regulation |
| transcription corepressor activity                          | 4  | Down-regulation |
| protein localization                                        | 20 | Down-regulation |
| protein transport                                           | 17 | Down-regulation |
| endoplasmic reticulum lumen                                 | 4  | Down-regulation |
| Golgi apparatus                                             | 18 | Down-regulation |
| membrane lipid metabolic process                            | 4  | Down-regulation |
| sphingolipid metabolic process                              | 4  | Down-regulation |
| glycolipid metabolic process                                | 3  | Down-regulation |
| carbohydrate biosynthetic process                           | 8  | Down-regulation |
| glucose metabolic process                                   | 7  | Down-regulation |
| activation of caspase activity by cytochrome c              | 2  | Down-regulation |
| calcium ion homeostasis                                     | 6  | Down-regulation |
| cellular calcium ion homeostasis                            | 6  | Down-regulation |
| potassium ion transport                                     | 6  | Down-regulation |
| regulation of membrane potential                            | 5  | Down-regulation |
| synaptic vesicle                                            | 5  | Down-regulation |
| regulation of transcription from RNA polymerase II promoter | 35 | N/A*            |
| transcription repressor activity                            | 16 | N/A*            |
| trans-Golgi network                                         | 6  | N/A*            |
| positive regulation of cell death                           | 17 | N/A*            |
| positive regulation of axon extension                       | 3  | N/A*            |
| response to light stimulus                                  | 9  | N/A*            |

\*N/A – Not applicable, result obtained by combining up- and down-regulated genes.

## F. 120 hours

| Biological Process and Pathway                             | Count | Change Direction |
|------------------------------------------------------------|-------|------------------|
| transcription                                              | 87    | Up-regulation    |
| regulation of transcription                                | 103   | Up-regulation    |
| mRNA metabolic process                                     | 19    | Up-regulation    |
| posttranscriptional regulation of gene expression          | 12    | Up-regulation    |
| spliceosome                                                | 10    | Up-regulation    |
| establishment of RNA localization                          | 7     | Up-regulation    |
| mRNA transport                                             | 6     | Up-regulation    |
| translation                                                | 29    | Up-regulation    |
| regulation of translation                                  | 9     | Up-regulation    |
| negative regulation of translation                         | 4     | Up-regulation    |
| translation factor activity, nucleic acid binding          | 14    | Up-regulation    |
| translational initiation                                   | 6     | Up-regulation    |
| translation initiation factor activity                     | 9     | Up-regulation    |
| translation elongation factor activity                     | 5     | Up-regulation    |
| ribonucleoprotein complex                                  | 36    | Up-regulation    |
| ribosome                                                   | 21    | Up-regulation    |
| ribosomal subunit                                          | 9     | Up-regulation    |
| large ribosomal subunit                                    | 6     | Up-regulation    |
| ribosomal protein                                          | 18    | Up-regulation    |
| protein complex assembly                                   | 19    | Up-regulation    |
| cellular protein complex assembly                          | 12    | Up-regulation    |
| regulation of protein complex assembly                     | 7     | Up-regulation    |
| protein localization                                       | 60    | Up-regulation    |
| establishment of protein localization                      | 50    | Up-regulation    |
| endomembrane system                                        | 37    | Up-regulation    |
| cellular protein localization                              | 25    | Up-regulation    |
| protein localization in organelle                          | 9     | Up-regulation    |
| protein localization in nucleus                            | 6     | Up-regulation    |
| protein transport                                          | 35    | Up-regulation    |
| intracellular protein transport                            | 23    | Up-regulation    |
| nucleocytoplasmic transport                                | 8     | Up-regulation    |
| protein targeting                                          | 12    | Up-regulation    |
| protein import                                             | 9     | Up-regulation    |
| protein import into nucleus                                | 6     | Up-regulation    |
| protein catabolic process                                  | 31    | Up-regulation    |
| cellular protein catabolic process                         | 30    | Up-regulation    |
| proteolysis involved in cellular protein catabolic process | 30    | Up-regulation    |
| ubl conjugation                                            | 35    | Up-regulation    |
| ubiquitin                                                  | 6     | Up-regulation    |
| ubiquitin-conjugating enzyme/RWD-like                      | 7     | Up-regulation    |
| proteasome                                                 | 6     | Up-regulation    |
| proteasome core complex                                    | 4     | Up-regulation    |
| proteasome, subunit alpha/beta                             | 4     | Up-regulation    |
| cytoskeleton organization                                  | 20    | Up-regulation    |
| regulation of cytoskeleton organization                    | 11    | Up-regulation    |
| regulation of microtubule cytoskeleton organization        | 8     | Up-regulation    |
| regulation of microtubule-based process                    | 8     | Up-regulation    |
| regulation of microtubule polymerization                   | 5     | Up-regulation    |
| microtubule polymerization                                 | 3     | Up-regulation    |
| cell motion                                                | 25    | Up-regulation    |

|                                                                  |    |               |
|------------------------------------------------------------------|----|---------------|
| cell motility                                                    | 20 | Up-regulation |
| localization of cell                                             | 20 | Up-regulation |
| cell migration                                                   | 18 | Up-regulation |
| cell-cell signaling                                              | 25 | Up-regulation |
| intracellular signaling cascade                                  | 46 | Up-regulation |
| MAPK signaling pathway                                           | 21 | Up-regulation |
| small GTPase mediated signal transduction                        | 19 | Up-regulation |
| transmembrane receptor protein tyrosine kinase signaling pathway | 13 | Up-regulation |
| transforming growth factor beta receptor signaling pathway       | 6  | Up-regulation |
| chaperone                                                        | 14 | Up-regulation |
| heat shock protein binding                                       | 7  | Up-regulation |
| Heat shock protein DnaJ, conserved site                          | 7  | Up-regulation |
| unfolded protein binding                                         | 8  | Up-regulation |
| unfolded protein response                                        | 5  | Up-regulation |
| response to endoplasmic reticulum stress                         | 4  | Up-regulation |
| ER overload response                                             | 3  | Up-regulation |
| triglyceride biosynthetic process                                | 3  | Up-regulation |
| mitochondrion                                                    | 66 | Up-regulation |
| respiratory chain                                                | 9  | Up-regulation |
| oxidative phosphorylation                                        | 5  | Up-regulation |
| ion transport                                                    | 40 | Up-regulation |
| ion homeostasis                                                  | 19 | Up-regulation |
| cellular ion homeostasis                                         | 18 | Up-regulation |
| Calcium signaling pathway                                        | 15 | Up-regulation |
| calcium ion transport                                            | 12 | Up-regulation |
| Gap junction                                                     | 8  | Up-regulation |
| transepithelial chloride transport                               | 3  | Up-regulation |
| neurogenesis                                                     | 11 | Up-regulation |
| regulation of growth                                             | 17 | Up-regulation |
| regulation of cell growth                                        | 9  | Up-regulation |
| regulation of endothelial cell proliferation                     | 4  | Up-regulation |
| mitotic cell cycle                                               | 16 | Up-regulation |
| interphase of mitotic cell cycle                                 | 6  | Up-regulation |
| cell morphogenesis                                               | 19 | Up-regulation |
| cell morphogenesis involved in neuron differentiation            | 15 | Up-regulation |
| chromatin                                                        | 12 | Up-regulation |
| chromatin regulator                                              | 15 | Up-regulation |
| chromatin modification                                           | 16 | Up-regulation |
| chromatin remodeling complex                                     | 7  | Up-regulation |
| histone acetylation                                              | 5  | Up-regulation |
| axonogenesis                                                     | 13 | Up-regulation |
| cellular component morphogenesis                                 | 21 | Up-regulation |
| cell projection organization                                     | 24 | Up-regulation |
| regulation of cell morphogenesis                                 | 8  | Up-regulation |
| neuron projection development                                    | 15 | Up-regulation |
| neuron projection morphogenesis                                  | 15 | Up-regulation |
| axon guidance                                                    | 14 | Up-regulation |
| dendrite                                                         | 10 | Up-regulation |
| presynaptic membrane                                             | 6  | Up-regulation |
| regulation of membrane potential                                 | 11 | Up-regulation |
| membrane depolarization                                          | 6  | Up-regulation |
| regulation of postsynaptic membrane potential                    | 6  | Up-regulation |
| regulation of excitatory postsynaptic membrane potential         | 5  | Up-regulation |

|                                               |    |                 |
|-----------------------------------------------|----|-----------------|
| transmission of nerve impulse                 | 24 | Up-regulation   |
| regulation of transmission of nerve impulse   | 12 | Up-regulation   |
| synaptic transmission                         | 20 | Up-regulation   |
| regulation of synaptic transmission           | 10 | Up-regulation   |
| Endocytosis                                   | 14 | Up-regulation   |
| regulation of synaptic plasticity             | 6  | Up-regulation   |
| regulation of neuronal synaptic plasticity    | 5  | Up-regulation   |
| Long-term potentiation                        | 12 | Up-regulation   |
| behavior                                      | 27 | Up-regulation   |
| learning or memory                            | 10 | Up-regulation   |
| memory                                        | 7  | Up-regulation   |
| locomotory behavior                           | 16 | Up-regulation   |
| response to light stimulus                    | 8  | Up-regulation   |
| visual behavior                               | 6  | Up-regulation   |
| visual learning                               | 5  | Up-regulation   |
| sensory perception of pain                    | 5  | Up-regulation   |
| response to ethanol                           | 4  | Up-regulation   |
| Alzheimer's disease                           | 15 | Up-regulation   |
| Amyotrophic lateral sclerosis (ALS)           | 8  | Up-regulation   |
| Huntington's disease                          | 14 | Up-regulation   |
| Parkinson's disease                           | 11 | Up-regulation   |
| aging                                         | 7  | Up-regulation   |
| response to drug                              | 10 | Up-regulation   |
| endoplasmic reticulum                         | 7  | Down-regulation |
| regulation of fatty acid biosynthetic process | 2  | Down-regulation |
| regulation of steroid biosynthetic process    | 2  | Down-regulation |
| negative regulation of cell differentiation   | 4  | Down-regulation |
| anti-proliferative protein                    | 2  | Down-regulation |
| neutral lipid biosynthetic process            | 3  | N/A*            |

\*N/A – Not applicable, result obtained by combining up- and down-regulated genes.

## G. 240 Hours

| Biological Process and Pathway                             | Count | Change Direction |
|------------------------------------------------------------|-------|------------------|
| mRNA metabolic process                                     | 14    | Down-regulation  |
| ncRNA metabolic process                                    | 10    | Down-regulation  |
| RNA processing                                             | 21    | Down-regulation  |
| mRNA processing                                            | 13    | Down-regulation  |
| ncRNA processing                                           | 8     | Down-regulation  |
| RNA splicing                                               | 9     | Down-regulation  |
| ribonucleoprotein complex                                  | 21    | Down-regulation  |
| endomembrane system                                        | 20    | Down-regulation  |
| endoplasmic reticulum                                      | 38    | Down-regulation  |
| endoplasmic reticulum part                                 | 15    | Down-regulation  |
| endoplasmic reticulum membrane                             | 10    | Down-regulation  |
| nuclear envelope-endoplasmic reticulum network             | 10    | Down-regulation  |
| ER-Golgi transport                                         | 6     | Down-regulation  |
| Golgi apparatus                                            | 28    | Down-regulation  |
| Golgi apparatus part                                       | 13    | Down-regulation  |
| trans-Golgi network                                        | 7     | Down-regulation  |
| protein localization                                       | 30    | Down-regulation  |
| establishment of protein localization                      | 25    | Down-regulation  |
| cellular protein localization                              | 12    | Down-regulation  |
| protein transport                                          | 22    | Down-regulation  |
| intracellular protein transport                            | 10    | Down-regulation  |
| vesicle-mediated transport                                 | 18    | Down-regulation  |
| cellular protein catabolic process                         | 19    | Down-regulation  |
| proteolysis involved in cellular protein catabolic process | 19    | Down-regulation  |
| ub1 conjugation pathway                                    | 18    | Down-regulation  |
| ER-associated protein catabolic process                    | 3     | Down-regulation  |
| autophagy                                                  | 5     | Down-regulation  |
| autophagy                                                  | 4     | Down-regulation  |
| macroautophagy                                             | 3     | Down-regulation  |
| lysosome                                                   | 9     | Down-regulation  |
| lipid biosynthetic process                                 | 12    | Down-regulation  |
| fatty acid biosynthetic process                            | 5     | Down-regulation  |
| mitochondrial inner membrane                               | 12    | Down-regulation  |
| generation of precursor metabolites and energy             | 10    | Down-regulation  |
| cellular response to nutrient levels                       | 4     | Down-regulation  |
| cytoplasmic vesicle                                        | 18    | Down-regulation  |
| intracellular receptor-mediated signaling pathway          | 4     | Down-regulation  |
| glutathione metabolism                                     | 5     | Down-regulation  |
| glutathione S-transferase, Mu class                        | 3     | Down-regulation  |
| glutathione S-transferase, N-terminal                      | 4     | Down-regulation  |
| glutathione S-transferase, C-terminal                      | 5     | Down-regulation  |
| glutathione S-transferase/chloride channel, C-terminal     | 5     | Down-regulation  |
| regulation of synaptic transmission                        | 6     | Down-regulation  |
| response to cold                                           | 3     | Down-regulation  |
| proteasomal protein catabolic process                      | 4     | N/A*             |
| proteasomal ubiquitin-dependent protein catabolic process  | 4     | N/A*             |
| fatty acid metabolic process                               | 9     | N/A*             |
| long-chain fatty acid metabolic process                    | 3     | N/A*             |
| learning                                                   | 5     | N/A*             |
| regulation of transmission of nerve impulse                | 7     | N/A*             |

|                                                   |    |      |
|---------------------------------------------------|----|------|
| intracellular receptor-mediated signaling pathway | 4  | N/A* |
| regulation of cell proliferation                  | 20 | N/A* |

\*N/A – Not applicable, result obtained by combining up- and down-regulated genes.

## H. 600 Hours

| Biological Process and Pathway                                       | Count | Change Direction |
|----------------------------------------------------------------------|-------|------------------|
| transcription                                                        | 193   | Up-regulation    |
| regulation of transcription                                          | 236   | Up-regulation    |
| positive regulation of transcription                                 | 54    | Up-regulation    |
| negative regulation of transcription                                 | 48    | Up-regulation    |
| positive regulation of gene expression                               | 54    | Up-regulation    |
| negative regulation of gene expression                               | 53    | Up-regulation    |
| positive regulation of transcription, DNA-dependent                  | 45    | Up-regulation    |
| negative regulation of transcription, DNA-dependent                  | 37    | Up-regulation    |
| regulation of transcription from RNA polymerase II promoter          | 65    | Up-regulation    |
| negative regulation of transcription from RNA polymerase II promoter | 31    | Up-regulation    |
| transcription factor complex                                         | 27    | Up-regulation    |
| mRNA metabolic process                                               | 51    | Up-regulation    |
| positive regulation of RNA metabolic process                         | 45    | Up-regulation    |
| mRNA processing                                                      | 43    | Up-regulation    |
| mRNA splicing                                                        | 36    | Up-regulation    |
| nuclear mRNA splicing, via spliceosome                               | 8     | Up-regulation    |
| spliceosome                                                          | 20    | Up-regulation    |
| posttranscriptional regulation of gene expression                    | 26    | Up-regulation    |
| mRNA transport                                                       | 11    | Up-regulation    |
| regulation of translation                                            | 21    | Up-regulation    |
| negative regulation of translation                                   | 8     | Up-regulation    |
| regulation of translational initiation                               | 7     | Up-regulation    |
| endomembrane system                                                  | 72    | Up-regulation    |
| nuclear envelope-endoplasmic reticulum network                       | 21    | Up-regulation    |
| endoplasmic reticulum membrane                                       | 19    | Up-regulation    |
| response to endoplasmic reticulum stress                             | 6     | Up-regulation    |
| ER-nuclear signaling pathway                                         | 6     | Up-regulation    |
| Golgi apparatus                                                      | 62    | Up-regulation    |
| protein localization                                                 | 81    | Up-regulation    |
| establishment of protein localization                                | 68    | Up-regulation    |
| protein transport                                                    | 66    | Up-regulation    |
| vesicle-mediated transport                                           | 49    | Up-regulation    |
| Golgi vesicle transport                                              | 9     | Up-regulation    |
| intracellular protein transport                                      | 31    | Up-regulation    |
| regulation of protein complex assembly                               | 12    | Up-regulation    |
| regulation of protein complex disassembly                            | 8     | Up-regulation    |
| positive regulation of protein complex assembly                      | 6     | Up-regulation    |
| Posttranslational modification, protein turnover, chaperones         | 20    | Up-regulation    |
| Molecular chaperone, heat shock protein, Hsp40, DnaJ                 | 8     | Up-regulation    |
| glycoprotein biosynthetic process                                    | 16    | Up-regulation    |
| protein amino acid glycosylation                                     | 14    | Up-regulation    |
| cellular protein catabolic process                                   | 71    | Up-regulation    |
| modification-dependent protein catabolic process                     | 70    | Up-regulation    |
| proteolysis involved in cellular protein catabolic process           | 71    | Up-regulation    |
| regulation of cellular protein metabolic process                     | 42    | Up-regulation    |
| Ubiquitin mediated proteolysis                                       | 24    | Up-regulation    |
| ubl conjugation                                                      | 76    | Up-regulation    |
| ubl conjugation pathway                                              | 71    | Up-regulation    |
| phospholipid metabolic process                                       | 21    | Up-regulation    |

|                                                       |    |               |
|-------------------------------------------------------|----|---------------|
| organophosphate metabolic process                     | 21 | Up-regulation |
| glycerophospholipid metabolic process                 | 14 | Up-regulation |
| mitochondrion inner membrane                          | 22 | Up-regulation |
| cell death                                            | 51 | Up-regulation |
| apoptosis                                             | 48 | Up-regulation |
| regulation of apoptosis                               | 64 | Up-regulation |
| positive regulation of apoptosis                      | 31 | Up-regulation |
| negative regulation of apoptosis                      | 31 | Up-regulation |
| regulation of cell death                              | 65 | Up-regulation |
| positive regulation of cell death                     | 31 | Up-regulation |
| negative regulation of cell death                     | 31 | Up-regulation |
| cell projection organization                          | 44 | Up-regulation |
| neuron differentiation                                | 43 | Up-regulation |
| neuron development                                    | 38 | Up-regulation |
| neuron projection                                     | 36 | Up-regulation |
| neuron projection development                         | 31 | Up-regulation |
| cell projection morphogenesis                         | 27 | Up-regulation |
| neuron projection morphogenesis                       | 25 | Up-regulation |
| cell morphogenesis involved in neuron differentiation | 25 | Up-regulation |
| axonogenesis                                          | 24 | Up-regulation |
| axon guidance                                         | 22 | Up-regulation |
| dendrite                                              | 19 | Up-regulation |
| dendrite development                                  | 8  | Up-regulation |
| dendritic shaft                                       | 5  | Up-regulation |
| postsynaptic density                                  | 11 | Up-regulation |
| postsynaptic membrane                                 | 17 | Up-regulation |
| presynaptic membrane                                  | 10 | Up-regulation |
| synapse                                               | 43 | Up-regulation |
| synapse part                                          | 29 | Up-regulation |
| synapse organization                                  | 11 | Up-regulation |
| synaptogenesis                                        | 8  | Up-regulation |
| ionotropic glutamate receptor, AMPA/kainate types     | 4  | Up-regulation |
| synaptic transmission                                 | 28 | Up-regulation |
| regulation of synaptic transmission                   | 19 | Up-regulation |
| neurotransmitter secretion                            | 8  | Up-regulation |
| synaptic vesicle transport                            | 7  | Up-regulation |
| synaptic vesicle targeting                            | 3  | Up-regulation |
| regulation of postsynaptic membrane potential         | 6  | Up-regulation |
| potassium ion transport                               | 22 | Up-regulation |
| calcium ion transport                                 | 16 | Up-regulation |
| calcium-dependent cell-cell adhesion                  | 4  | Up-regulation |
| cell motion                                           | 45 | Up-regulation |
| cell migration                                        | 29 | Up-regulation |
| neuron migration                                      | 11 | Up-regulation |
| telencephalon cell migration                          | 6  | Up-regulation |
| forebrain development                                 | 25 | Up-regulation |
| pallium development                                   | 10 | Up-regulation |
| cerebral cortex development                           | 8  | Up-regulation |
| forebrain cell migration                              | 6  | Up-regulation |
| cerebral cortex cell migration                        | 6  | Up-regulation |
| cellular response to stress                           | 45 | Up-regulation |
| response to insulin stimulus                          | 10 | Up-regulation |
| cellular response to heat                             | 5  | Up-regulation |

|                                                            |     |                 |
|------------------------------------------------------------|-----|-----------------|
| intracellular signaling cascade                            | 92  | Up-regulation   |
| MAPK signaling pathway                                     | 43  | Up-regulation   |
| Phosphatidylinositol signaling system                      | 13  | Up-regulation   |
| Insulin signaling pathway                                  | 28  | Up-regulation   |
| Wnt signaling pathway                                      | 22  | Up-regulation   |
| Neurotrophin signaling pathway                             | 25  | Up-regulation   |
| GnRH signaling pathway                                     | 17  | Up-regulation   |
| ErbB signaling pathway                                     | 19  | Up-regulation   |
| TGF-beta signaling pathway                                 | 15  | Up-regulation   |
| VEGF signaling pathway                                     | 14  | Up-regulation   |
| mTOR signaling pathway                                     | 11  | Up-regulation   |
| NOD-like receptor signaling pathway                        | 11  | Up-regulation   |
| Transcription factor CREB and its extracellular signals    | 7   | Up-regulation   |
| Chemokine signaling pathway                                | 23  | Up-regulation   |
| B cell receptor signaling pathway                          | 17  | Up-regulation   |
| T cell receptor signaling pathway                          | 19  | Up-regulation   |
| Toll-like receptor signaling pathway                       | 17  | Up-regulation   |
| cytoskeleton                                               | 105 | Up-regulation   |
| regulation of cytoskeleton organization                    | 15  | Up-regulation   |
| microtubule                                                | 24  | Up-regulation   |
| microtubule organizing center                              | 20  | Up-regulation   |
| actin cytoskeleton organization                            | 19  | Up-regulation   |
| regulation of actin filament-based process                 | 10  | Up-regulation   |
| regulation of actin cytoskeleton organization              | 9   | Up-regulation   |
| actin cytoskeleton reorganization                          | 4   | Up-regulation   |
| dynein complex                                             | 6   | Up-regulation   |
| cell cycle                                                 | 63  | Up-regulation   |
| chromosome organization                                    | 44  | Up-regulation   |
| chromatin modification                                     | 30  | Up-regulation   |
| chromatin regulator                                        | 23  | Up-regulation   |
| mitotic sister chromatid segregation                       | 5   | Up-regulation   |
| histone methylation                                        | 6   | Up-regulation   |
| cell adhesion                                              | 61  | Up-regulation   |
| cell junction                                              | 46  | Up-regulation   |
| Adherens junction                                          | 13  | Up-regulation   |
| cell-cell adhesion                                         | 32  | Up-regulation   |
| Focal adhesion                                             | 34  | Up-regulation   |
| Gap junction                                               | 12  | Up-regulation   |
| blood vessel development                                   | 28  | Up-regulation   |
| Long-term potentiation                                     | 15  | Up-regulation   |
| Long-term depression                                       | 14  | Up-regulation   |
| regulation of synaptic plasticity                          | 13  | Up-regulation   |
| regulation of neuronal synaptic plasticity                 | 8   | Up-regulation   |
| regulation of long-term neuronal synaptic plasticity       | 7   | Up-regulation   |
| behavior                                                   | 49  | Up-regulation   |
| adult locomotory behavior                                  | 11  | Up-regulation   |
| Alzheimer's disease                                        | 20  | Up-regulation   |
| Glioma                                                     | 16  | Up-regulation   |
| learning or memory                                         | 17  | Up-regulation   |
| learning                                                   | 10  | Up-regulation   |
| cellular protein catabolic process                         | 7   | Down-regulation |
| modification-dependent protein catabolic process           | 7   | Down-regulation |
| proteolysis involved in cellular protein catabolic process | 7   | Down-regulation |

|                                                     |    |                 |
|-----------------------------------------------------|----|-----------------|
| ubl conjugation pathway                             | 7  | Down-regulation |
| Ubiquitin mediated proteolysis                      | 4  | Down-regulation |
| microtubule                                         | 4  | Down-regulation |
| Cell cycle                                          | 4  | Down-regulation |
| regulation of protein polymerization                | 10 | N/A*            |
| Chaperone                                           | 20 | N/A*            |
| protein folding                                     | 17 | N/A*            |
| negative regulation of neuron apoptosis             | 9  | N/A*            |
| positive regulation of cell projection organization | 6  | N/A*            |
| microtubule cytoskeleton                            | 52 | N/A*            |
| Regulation of actin cytoskeleton                    | 28 | N/A*            |
| chromatin organization                              | 35 | N/A*            |
| ATP biosynthetic process                            | 13 | N/A*            |
| vasculature development                             | 30 | N/A*            |

\*N/A – Not applicable, result obtained by combining up- and down-regulated genes.